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 The concept that structure defines function is fundamental to understanding 
biology and this theme is repeated again and again at the molecular, cellular, and 
organism levels.  Remarkable advances in X-ray crystallography allow scientists to 
probe the structure of enzymes at atomic resolution.  Protein crystal structures allow a 
greater understanding of the chemical and biological functions of these cellular 
machines.  Enzymes from prokaryotes that are involved in the biosynthesis and 
degradation of various metabolites often present novel chemistry and curious 
functionalities.  The enzymes classified in the nucleoside 2!-deoxyribosyltransferase 
superfamily have conserved catalytic residues and share a mechanism for the N-
glycosidic bond cleavage of nucleosides, but demonstrate varied substrate specificity 
and biochemical functions.  The structures of two members of this superfamily, 
Streptomyces rimofaciens MilB and Clostridium botulinum BcmB, provide novel 
information about how these enzymes confer specificity at their substrate 2!-position.   
 The biosynthetic pathways of bacterial natural products also frequently present 
enzymes with unique functions and specificities.  To better understand the biology of 
the thiamin antimetabolite bacimethrin, the C. botulinum genes responsible for its 
 biosynthesis were identified and several enzymes implicated in its production were 
structurally characterized.  Here, the structure of the bacimethrin kinase, BcmD is 
analyzed to better understand its specificity and relationship to other ribokinases.  
Another enzyme clustered with the bacimethrin genes, Cb-thiaminase I, was thought 
to serve as a bacimethrin-detoxifying enzyme.  While this was not supported, 
structural solution and supporting kinetic characterization provides a new mechanistic 
understanding of the thiaminase I class of enzymes.  Finally, the biosynthetic genes for 
the Streptomyces sahachiroi antitumor antibiotic, azinomycin B, were recently 
identified and reveal a complex network of enzymes involved in its assembly.  
Biochemical studies suggest that production of the azinomycin B naphthoate moiety 
requires a thioesterase enzyme in addition to a polyketide synthase megaenzyme.  
Structural characterization of the thioesterase SsAziG co-crystallized with a product 
analog supports this finding and provides a basis for its proposed mechanism. 
  v 
BIOGRAPHICAL SKETCH 
Megan was born and raised in the Maryland suburbs of Washington, D.C.  She 
is the second of three children to her parents, Pam and Matt Sikowitz. She attended 
Eleanor Roosevelt High School in Greenbelt, MD, where she participated in the 
Science and Technology program and her favorite classes were Chemistry and Band.  
In 2004, she started undergraduate studies at St. Mary’s College of Maryland; 
Maryland’s public liberal arts honors college.  Megan was initially a Biology major at 
St. Mary’s until developing a fascination with Organic Chemistry.  She switched 
departments and became a Biochemistry major in order to focus on more chemistry 
oriented courses.  While at St. Mary’s she also completed a Mathematics minor and 
competed on the rowing team.   
Megan had the opportunity to gain research experience in a synthetic organic 
chemistry lab at St. Mary’s.  While interesting, enzymes intrigued her more.  After 
spending a summer in the laboratory of Prof. Nicole Sampson at Stony Brook 
University studying enzymatic synthesis of sterol derivatives, Megan completed her 
senior thesis at the University of Maryland Chesapeake Biological Laboratory 
studying the marine enzyme DMSP lyase.  Because of these research experiences and 
enjoying her work as a TA, she decided to pursue a PhD in order to be able to teach 
and conduct research with undergraduates.   Megan joined the Chemistry and 
Chemical Biology department at Cornell University in 2008.  After completing her 
coursework, she began studying enzyme structure in Prof. Steven Ealick’s research 
group.  Her work has focused primarily on enzymes involved in bacimethrin and 
azinomycin B metabolism.  In her free time she has enjoyed exploring the parks and 
  vi 
wineries of upstate New York, running around Ithaca, and playing oboe with the 
Ithaca Concert Band.  She is relocating to the Washington, DC area and will marry 
Tom Erb in May 2014.  She is excited for continuing her adventures in a warmer 
climate.
  vii 
 
 
 
 
 
 
 
 
 
 
 
 
In memory of my dear Aunt Sue, who nurtured my love of learning, and my cousin 
Jacob Vogelman, a true mensch.
  viii 
ACKNOWLEDGMENTS 
First I would like to thank Prof. Steven Ealick for serving as my research 
advisor.  Thank you for allowing me to work on interesting projects, providing many 
opportunities to enhance my understanding of structural biology, and encouraging 
independent scientific thought.    I would also like to thank Prof. Hening Lin and Prof. 
Richard Cerione for their advice on research and for serving on my committee.  My 
thesis work would not have been possible without many wonderful collaborators.  I 
would like to acknowledge Prof. Coran Watanabe, her former student, Dr. Jennifer 
Foulke, and former post-doctoral scientist, Dr. Dinesh Simkhada, for their biochemical 
work on the azinomycin B project and thank them for many helpful discussions.  I also 
owe much gratitude to Prof. Tadgh Begley for his collaboration on the bacimethrin 
project.  Many thanks to his former postdoctoral scientist, Dr. Lisa Cooper, for her 
characterization of the bacimethrin enzymes and MilB, as well as his graduate student, 
Brateen Shome, for his work on Cb-thiaminase I.  Thanks also to Dr. Cynthia 
Kinsland for general advice on working with proteins and for providing countless 
clones and mutants.  I would also like to acknowledge Ms. Leslie Kinsland for her 
kindness and help she has provided in so many ways.  The NE-CAT staff has been 
incredibly helpful and offered much practical advice on data collection.  I have 
enjoyed working with them.  I thank current and former members of the Ealick group 
for their camaraderie and discussions that have both helped me with research and 
provided many enjoyable days in lab.  Finally, thanks to my parents, siblings, family, 
and friends for their support.  Special thanks to Tom, Erika, Angie, Katherine, and 
Erin for helping make Ithaca my home over the past five years. 
 
 
 
  ix 
 
TABLE OF CONTENTS 
 Page 
Biographical Sketch v 
Dedication vii 
Acknowledgements viii 
Table of Contents ix 
List of Figures x 
List of Tables xii 
List of Abbreviations xiii 
Chapter 1. Introduction 1 
Chapter 2. Reversal of substrate specificity of CMP N-glycosidase to 
dCMP 
 
17 
Chapter 3. Structure of Clostridium botulinum thiaminase I-thiamin 
complex reveals biochemical details of binding and degradation 
 
57 
Chapter 4.  Structure-function studies on Clostridium botulinum 
bacimethrin kinase, BcmD 
 
88 
Chapter 5.  Structural characterization of SsAziG, a Streptomyces 
sahachiroi thioesterase involved in azinomycin B biosynthesis 
 
106 
Chapter 6. Summary 127 
 x 
LIST OF FIGURES 
 Page 
Figure 1.1.  General mechanism for nucleobase transfer or hydrolysis by NDT 
superfamily members 
 
3 
Figure 1.2.  Substrate preferences of NDT superfamily members 4 
Figure 1.3.  General thiamin biosynthesis scheme 6 
Figure 1.4.  Thiamin degradation by thiaminase I and II 7 
Figure 1.5.  Bacimethrin biosynthesis in Clostridium botulinum 9 
Figure 1.6.  Chemical structure of the azinomycins  10 
Scheme 2.1.  MilB mechanism 46 
Figure 2.1. Natural products with cytosine precursors 20 
Figure 2.2. Structure of MilB 29 
Figure 2.3. Substrate binding in MilB 31 
Figure 2.4. BcmB/PO4 and MilB/CMP active site comparison 32 
Figure 2.5. Substrate specificity of MilB WT and MilB F17Y 34 
Figure 2.6. Comparison of enzyme dimerization 37 
Figure 2.7. Sequence alignment of enzymes containing the nucleoside 2!-
deoxyribosyltransferase motif 
 
40 
Figure 2.8. NDT family member active site comparison 44 
Figure 2.9. Active site comparison of MilB and NDT 47 
Figure S2.1.  No hydrolysis of purines by MilB 49 
Figure S2.2. BcmB structure 50 
Figure S2.3. BcmB WT and F6Y reaction with CMP and dCMP 51 
Figure 3.1. Thiamin cleavage reaction catalyzed by the thiaminases 57 
 xi 
Figure 3.2. Overall structure of C143S/Thiamin 67 
Figure 3.3.  C143S/Thiamin active site interactions  69 
Figure 3.4 Thiamin binding in C143S 69 
Figure 3.5. Comparison of C143S/Thiamin with Thiaminase I/ACDP 
structure from B. thiaminolyticus 
 
72 
Figure 3.6. Mechanism of thiamin degradation by Cb-thiaminase I 79 
Figure 3.7. Sequence alignment of thiaminase Is  80 
Figure 3.8. Comparison of thiamin binding in Thiaminase I and II 81 
Figure 4.1. Routes to thiamin pyrophosphate (ThDP) and 2'-methoxythiamin 
pyrophosphate biosynthesis (MeOThDP).   
 
89 
Figure 4.2.  Bacimethrin biosynthesis pathway 90 
Figure 4.3. Structure of BcmD 96 
Figure 4.4. Stereoview of BcmD active site aligned with StHMPP 
kinase/HMP and two sulfates 
 
94 
Figure 4.5.  BcmD/StHMPP kinase sequence alignment.   98 
Figure 4.6.  HMPP kinase/BcmD active site binding flap movement upon 
substrate binding 
 
102 
Figure 5.1.  Structure of the azinomycins and synthesis of the naphthoate 107 
Figure 5.2. Monomeric structure of AziG 114 
Figure 5.3.  The biological tetramer formed by AziG 115 
Figure 5.4.  AziG active site 116 
Figure 5.5.  Model for 5-methyl-NPA binding  117 
Figure 5.6. Proposed mechanism for 5-methyl-NPA-CoA hydrolysis by AziG 120 
 xii 
LIST OF TABLES 
 Page 
Table 2.1.  Summary of MilB/BcmB data collection and refinement 
statistics. 
 
26 
Table 2.2.  Summary of MilB/BcmB kinetic data 35 
Table 2.3. Enzymes structurally similar to MilB  36 
Table 2.4. Summary of NDT-superfamily enzymes 38 
Table  S2.1.  Enzyme/substrate concentrations used in kinetic assays 48 
Table 3.1. Summary of C143S/thiamin data collection and refinement 
statistics  
 
65 
Table 3.2. Kinetic properties of thiaminase activity for Cb-thiaminase I 
WT and active site mutants 
 
70 
Table 3.3. Enzymes structurally similar to Cb-thiaminase I 71 
Table 4.1.  Summary of BcmD data collection and refinement statistics 94 
Table 4.2.  Summary of proteins structurally similar to BcmD 100 
Table 5.1. AziG data collection and refinement statistics 112 
Table 5.2.  Summary of proteins structurally similar to SsAziG, as 
analyzed by DALI  
119 
 xiii 
  LIST OF ABBREVIATIONS 
NDT, nucleoside 2!-deoxyribosyltransferase 
hmCMP, 5-hydroxymethyl cytidine 5!-monophosphate 
CMP, cytidine 5!-monophosphate; SeMet, selenomethionyl 
AMP, adenosine 5!-monophosphate; IMP, inosine 5!-monophosphate 
UMP, uridine 5!-monophosphate 
dCMP, 2!-deoxycytidine 5!-monophosphate 
GMP, guanosine 5!-monophosphate 
SAD, single-wavelength anomalous diffraction 
PTD, purine deoxyribosyltransferase 
DMHA, N,N-dimethylhexylamine 
5MD, 5-methyl-2'-deoxypseudouridine 
ADCP, 4-amino-6-chloro-2, 5-dimethylpyridimine 
PBP, periplasmic binding protein 
ThDP, thiamin pyrophosphate 
HMP-PP, 4-amino-5-hydroxymethyl-2-methylpyrimidine pyrophosphate 
THZ-P, thiazole phosphate carboxylate 
ThMP, thiamin monophosphate 
BCM, bacimethrin 
MeOThDP, 2!-methoxythiamin pyrophosphate 
IPTG, isopropyl-"-D-1-thiogalactopyranoside 
PKS, polyketide synthase 
NPA, naphthoic acid 
CHESS, Cornell High Energy Synchrotron Sournce 
rmsd, root mean squared deviation 
! "!
CHAPTER 1 
INTRODUCTION 
Section 1.1. Structural Biology 
Structural biologists use a wide array of tools to probe the three-dimensional 
arrangement of macromolecules.  While structural biology is a diverse field, the basic 
goal of all structural investigations is to reveal the basis of molecular interactions.  
Atomic structures offer a greater understanding of a protein’s biochemistry, which 
provides a context for understanding its role in cellular function.  Many tools have 
been developed for probing protein structure.  Among the most popular are nuclear 
magnetic resonance, electron microscopy, small angle X-ray scattering, and X-ray 
crystallography.1   While each of these methods is valuable, X-ray crystallography is 
the most versatile and powerful tool for solving atomic resolution protein structures 
currently available.  The work of X-ray crystallographers is prominently recognized in 
the scientific community.  In the past seven years alone, three Nobel Prizes in 
Chemistry have been awarded to protein crystallographers.2-4 Their work has led to 
groundbreaking advances in understanding fundamental biology upon which much 
biomedical research has been built. 
The X-ray crystallography experiment is straighforward in principle.  First, 
protein crystals are grown and then irradiated with X-rays.  The X-rays are scattered 
by the electrons in the crystal and the resultant diffracting X-rays are recorded by a 
detector.  From the diffraction data, a three-dimensional map of the electron density is 
calculated using Fourier methods.  Finally an atomic model of the molecule is built 
into the electron density.  In practice, solving an X-ray crystal structure presents many 
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challenges.  A major caveat of this method is known as the ‘phase problem’.   The 
phase of the diffracted X-ray is an essential component in calculating the Fourier 
transformations of the diffraction data.5  Because X-rays cannot be focused, 
information about their phases cannot be measured during the experiment.5   The 
development of anomalous dispersion6, isomorphous replacement7, and molecular 
replacement8 methods provides tools for the determination of phases.  Validation 
methods and data collection statistics exist to assess the quality of the model and 
reporting of this information is expected concurrent with publication of a protein 
structure.  The field of X-ray crystallography is quite mature, with over 78,000 atomic 
coordinate files publicly shared by members of the X-ray crystallography community 
in the Protein Data Bank (PDB).   
 The enzyme active site is often the area of most interest in a biochemical 
investigation.  Structural information is used to identify active site amino acids and 
cofactors.  This data is coupled with complementary kinetic and mutant studies to 
predict the mechanism of action.  These findings are then used to understand 
fundamental biochemistry and can be exploited for drug or inhibitor design if the 
enzyme target is involved in disease progression.  In the following chapters, X-ray 
crystallography and supporting biochemical studies are utilized to study the function, 
substrate specificity, and/or mechanisms of enzymes in various bacterial pathways that 
play important roles in nucleotide, thiamin, bacimethrin, and azinomycin B 
metabolism, including MilB, BcmB, Cb-thiaminase I, BcmD, and AziG.   
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Section 1. 2. Nucleoside 2!-deoxyribosyltransferases 
 Enzymes in the nucleoside 2!-deoxyribosyltransferase (NDT) superfamily 
catalyze the cleavage of the N-glycosidic bond of either nucleosides or nucleotides.  
Members of this family have conserved active site nucleophilic amino acids and share 
a common mechanism in which the nucleobase is replaced by an acceptor nucleophile 
(Figure 1.1).9, 10 However, they differ in their substrate preferences and final acceptor 
(Figure 1.2).  They also fulfill diverse physiological functions and are found in a wide 
variety of organisms.  Because of the varied functionalities of enzymes in this 
superfamily, their structures were analyzed to determine the basis of their substrate 
preferences.   
 
 
Figure 1.1.  General mechanism for nucleobase transfer or hydrolysis by NDT 
superfamily members 
The first member in this superfamily to be structurally characterized was 
Lactobacillus leichmanii NDT.11  NDTs are implicated in nucleoside salvage in 
organisms that lack the common nucleoside biosynthesis pathways and in regulation 
of nucleoside availability.12  They catalyze the reversible transfer of nucleobases from 
a deoxyribose, with highly flexible substrate specificity for both naturally occurring 
and synthetic nucleobases.13-15  Similarly, purine 2!-deoxyribosyltransferases (PTD) 
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are found in some prokaryotes and catalyze a transferase reaction, but accept only 
substrates with purine nucleobases.14  Rcl is a purine nucleotide hydrolase that 
provides much curiosity because it retains the conserved NDT mechanism, but utilizes 
water as the final acceptor.16, 17  It also stands out in this class because it functions in 
the regulation of cell growth and is found exclusively in mammals.  Unlike NDT and 
PTD, which only accept the 5!-hydroxyl containing nucleosides, Rcl shows specificity 
for the 5!-phosphate containing nucleotides. 
 
Figure 1.2.  Substrate preferences of NDT superfamily members 
 
In Chapter Two, the structures of two additional members of the NDT 
superfamily are analyzed.  BcmB and MilB, with 47% sequence identity to each other, 
are responsible for the hydrolysis of the N-glycosidic bond of cytidine 5!-
monophosphate (CMP) or 5-hydroxymethyl-CMP (hmCMP).  This reaction releases 
the cytosine portion for incorporation into their respective natural product biosynthesis 
pathways.18  CMP is a 2!-hydroxy containing substrate and is the first example of a 
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ribosylnucleotide substrate for an enzyme in this family.  This specificity is especially 
interesting because previous studies show ribosylnucleotides act as inhibitors of both 
Rcl and NDT.19  The structures of BcmB and MilB reveal that BcmB Phe6 and MilB 
Phe17 are near the substrate 2!-binding site and  are the basis of their specificity 
towards the ribosyl containing substrates.  In previously solved structures of other 
NDT family members, a tyrosine residue is positioned equivalently to this 
phenylalanine.  Finally, MilB and BcmB mutants were engineered for the reversal of 
substrate specificity to the 2!-deoxy containing dCMP by mutation of the 
phenylalanine to tyrosine.  The basis of the specificity of BcmB and MilB at the 
nucleotide 2!-position is further explored in Chapter Two. 
Section 1.3. Thiamin Degradation 
 Thiamin (vitamin B1) is important for many biological processes.  It stabilizes 
carbanion intermediates in essential metabolic pathways and its deficiency can lead to 
illness or death.20, 21  The biochemistry of thiamin has been of interest since the 
1950’s22 and its metabolism still yields fascinating chemical and biological questions.  
The biosynthetic pathways that produce thiamin have been extensively characterized.  
While the individual steps differ in prokaryotes and eukaryotes, both follow a two-
branched pathway in which the two heterocyclic halves of thiamin are synthesized 
separately, then ligated together to form thiamin.20  Thiamin phosphate kinase then 
generates the active form of thiamin, thiamin diphosphate (ThDP)23, 24 (Figure 1.3). 
! "!
 
Figure 1.3.  General thiamin biosynthesis scheme.  Bacimethrin biosynthesis 
metabolites and enzymes are distinguished in blue. 
 The physiological necessity for thiamin biosynthesis is clear, but the 
physiological purpose for thiamin degradation is not as well understood.  Two classes 
of thiamin degrading enzymes, thiaminase I and II, are known.20  Members of both 
classes can catalyze the degradation of thiamin into its thiazole and pyrimidine 
moieties.   Thiaminase Is utilize a variety of nucleophiles for CN bond cleavage,25 
whereas thiaminase IIs exclusively use water26 (Figure 1.4).  Thiaminase I tolerates 
substrate modifications on the thiamin thiazole moiety, including the phosphorylated 
thiamin forms ThDP and thiamin monophosphate (ThMP).  Thiaminase IIs do not 
accept these phosphorylated thiamin forms that are abundant in the cell.  The 
structural basis for this is established, as thiaminase II is an all !-helix bundle and its 
deep binding pocket limits accessibility.26  While it is able to degrade thiamin, its true 
function is to serve as a thiamin salvage enzyme, with base degraded thiamin as its 
preferred substrate.27  The structure and mechanism of thiaminase I differs from 
thiaminase II. 
Thiaminase I is found in some species of plants, fish, and bacteria.20  The first 
structure of a thiaminase I, from Bacillus thiaminolyticus with a mechanism based 
inhibitor, revealed its active site binding pocket.28  Thiaminase Is feature an open V-
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shaped binding cleft and display a conserved periplasmic binding protein (PBP) fold.  
PBPs have evolved to accommodate various substrates for transport and delivery of 
metabolites.29  The PBP fold architecture enables flexibility in substrate binding of 
thiamin, ThMP, and ThDP, with additional accessibility for a variety of nucleophiles.  
Thiaminase I is infamous for its role in the deaths of Australian explorers in the 1860’s 
who consumed the native nardoo fern.20  Unbeknownst to them, this plant contains 
large amounts of thiaminase I.  As a result of ingesting it, the explorers had 
insufficient cellular levels of thiamin, which led to their deaths by the thiamin 
deficiency disease, beriberi.  Even after decades of study, the physiological purpose 
for producing thiaminase I remains mysterious. 
 
Figure 1.4.  Thiamin degradation by thiaminase I and II 
 
In Chapter Three, the structure of  Cb-thiaminase I from Clostridium 
botulinum is explored.  Cb-thiaminase I is clustered with the genes from the newly 
discovered bacimethrin (BCM) biosynthesis pathway.  Introduced in detail in section 
1.4, BCM is a thiamin antimetabolite.  Briefly, BCM is an analog to the thiamin 
precursor hydroxymethyl pyrimidine (HMP) and it hijacks the thiamin biosynthetic 
machinery30 to produce a biologically insufficient thiamin analog (Figure 1.3).  The 
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original hypothesis that Cb-thiaminase I serves to detoxify BCM turned out to be 
incorrect (Cooper, et. al., Begley Lab- manuscript in preparation).  However, the 
crystal structure of a catalytically inactive Cb-thiaminase I cocrystallized with thiamin 
aided in identification of key residues involved in catalysis of thiamin degradation.   
Based on these structural details along with supporting kinetic studies, a detailed 
mechanism for the thiaminase I reaction is proposed. The physiological purpose of 
thiamin degradation still remains to be discovered, but the details of thiaminase I 
chemistry are now clear. 
Section 1.4.  Bacimethrin 
 BCM is a thiamin antimetabolite toxic to yeast and bacteria.  Initially thought 
to be an inhibitor of thiamin biosynthesis enzymes,31 it was later shown that BCM is in 
fact a substrate for these enzymes.30  BCM differs from the thiamin precursor HMP by 
the addition of a methoxy group at the O2 position.   In E. coli treated with BCM or 
HMP, in vitro conversion of BCM to 2!-methoxythiamin is six times faster than HMP 
conversion to thiamin, suggesting BCM overwhelms the thiamin biosynthetic 
pathway.30 The abundance of this biologically insufficient thiamin analog leads to 
toxic effects and toxicity is reversed by addition of thiamin to the growth media.31   
The BCM biosynthetic pathway was recently identified in C. botulinum 
(Figure 1.5) (Cooper, et. al., Begley Lab- manuscript in preparation).  In addition to 
providing a basis for understanding the origin of BCM, the functions of enzymes in 
this pathway raise interesting biochemical questions. BcmA is responsible for the 
addition of a 5-hydroxymethyl group to the CMP precursor.  Next BcmB, a member of 
a small family of ribosylnucleotide hydrolases introduced in Section 1.2, hydrolyzes 
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the N-glycosidic of hmCMP.  After further methylation at the cytosine O2 by BcmC, 
BCM is prepared for shuttling into the thiamin metabolic pathway by BcmD 
diphosphorylation.   
 BcmB and Cb-thiaminase I (found clustered with the BCM biosynthesis genes) 
are discussed in Chapters 2 and 3, respectively.  BcmD is highly similar in sequence 
and structure to known HMPP kinases.  It is structurally homologous to several 
ribokinases and is able to phosphorylate both BCM and HMP.  Comparison of the 
BcmD structure to the thiamin biosynthesis HMPP kinase establishes a close 
relationship and conservation of active site architecture.  The substrate flexibility and 
preferences of BcmD and its role in BCM toxicity are explored in Chapter Four.   
 
 
 
 
Figure 1.5 Bacimethrin biosynthesis in Clostridium botulinum 
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Section 1.5.  Azinomycin B Biosynthesis 
Complex natural products with antibiotic properties are frequently found in 
bacteria.  Chemical biologists study their functionalities and mechanism of action in 
an effort to develop new drug compounds.  The azinomycins are one class of natural 
products of interest32 (Figure 1.6).  Isolated from Streptomyces sahachiroi and 
Steptomyces griseofuscus,33, 34 azinomycin B has antitumor antibiotic activity and 
shows activity at the nanomolar level against some cancers in mouse models.35  
Mechanistically, azinomycin B crosslinks DNA by electrophilic attack on to the N7 
position of purines with apparent sequence selectivity. 36 Chemically, azinomycin B is 
of interest because of its unique tailoring and densely assembled functional groups.  
While fermentation methods have been exploited to obtain azinomycin B for some 
time,33 the genes responsible for the biosynthesis of azinomycin B were only recently 
identified in S. sahachiroi.34   
 
Figure 1.6.   Chemical structure of the azinomycins  
 
Initial reports suggested that the S. sahachiroi polyketide synthase encoded by 
the aziB gene, SsAziB, is the only enzyme in the pathway necessary for production of 
the azinomycin B naphthoate moiety.34, 37  Recent findings suggest that SsAziB acts in 
concert with a thioesterase, SsAziG, to produce the naphthoate fragment (Watanabe 
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Lab- manuscript in preparation).   SsAziB polymerizes and condenses acetyl-CoA 
and malonyl-CoA precursor molecules and then SsAziG hydrolyzes the 5-methyl-
naphthate-CoA thioester bond to release the product.   In Chapter 5, crystallographic 
studies of SsAziG with the bound product analog, 3-hydroxy-2-naphthoic acid, 
provide evidence that supports these new biochemical findings.  Structural 
comparisons between SsAziG and related thioesterases support the function of SsAziG 
in naphthoate biosynthesis and a possible mechanism.   
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CHAPTER 2 
REVERSAL OF SUBSTRATE SPECIFICITY OF CMP N-GLYCOSIDASE TO 
dCMP 
Section 2.1. Introduction 
MilB is an enzyme involved in the biosynthesis of the natural product 
mildiomycin (Figure 2.1A), a commercially available antifungal agent isolated from 
Streptomyces rimofaciens.1-3  MilB preferentially hydrolizes the N-glycosidic bond of 
5-hydroxymethyl cytidine 5!-monophosphate (hmCMP)  to release 5-hydroxymethyl 
cytosine, which is later incorporated into mildiomycin (Figure 2.1B).1  Previous 
studies found that MilB also hydrolyzes cytidine 5!-monophosphate (CMP) to its 
cytosine and ribose 5!-phosphate (Figure 2.1B).1  MilB is a member of the 2!-
deoxynucleoside ribosyltransferase (NDT) superfamily.  Typically, NDTs catalyze the 
reversible transfer of 2!-deoxyribose from a donor 2!-deoxynucleoside to an acceptor 
base.  Their structural and functional properties have been investigated in detail.4-6  
NDTs are found in a limited number of organisms and are thought to be important for 
nucleoside recycling when alternative nucleoside salvage pathways do not exist.5  In 
contrast to most NDTs, MilB participates in a hydrolysis reaction, in which the 
acceptor base is replace by a water molecule.  While NDT exhibits hydrolysis activity 
in the absence of an acceptor base, the hydrolysis activity is about 100-fold lower than 
its transferase reaction.6   
BLAST analyses starting with the MilB sequence suggest homology to BcmB 
from Clostridium botulinum (47% sequence identity).  Like MilB, BcmB also shows 
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CMP hydrolase activity, but is utilized in a different biosynthetic pathway.  BcmB is 
responsible for the production of the 5-hydroxymethylcytosine precursor for the 
biosynthesis of bacimethrin, a thiamin antimetabolite found in C. botulinum (Figure 
2.1)  (T.P. Begley, manuscript in preparation).  While MilB and BcmB both belong to 
the NDT superfamily, they differ from other members of this family in their substrate 
preferences.  Most enzymes containing the NDT-motif are specific for 2!-
deoxynucleosides.4, 7  MilB and BcmB hydrolize hmCMP, a ribonucleotide containing 
5!-monophosphate and 2!-hydroxy groups.   
In addition to MilB and BcmB, several other enzymes containing the NDT 
motif function as nucleoside transferases.  BlsM from Streptomyces 
griseochromogenes (52% sequence identity to MilB) is a nucleotide hydrolase, with 
CMP as the preferred substrate.  The cytosine produced from the BlsM reaction is 
incorporated into blasticidin S, a commercially available antibiotic compound (Figure 
2.1A).8   Rcl, another member of the NDT superfamily, catalyzes the hydrolysis of 
purine 2!-deoxyribosylnucleotides and is inhibited by ribonucleotides.9  Its solution 
structure,10, 11 and recent crystal structures with bound inhibitors,12 provide highly 
detailed information about its substrate-enzyme interactions.  Rcl is unusual because it 
is the only NDT family member found in mammals.  Rcl is upregulated in some 
cancers and contributes to tumorigenesis; however, the details of its cellular function 
are unclear.13, 14     
Because members of the NDT superfamily are not widely distributed and they 
show significant variation in substrate specificity, their evolution is not clearly 
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understood.  Conservation of key active site residues suggests a common catalytic 
mechanism even though the substrates for different family members vary in their 
preference for ribosyl or 2!-deoxyribosyl groups, 5!-hydroxyl or 5!-phosphate groups, 
and the type of nucleobase.  Here we report the X-ray structures of MilB and BcmB, 
and of MilB complexed with CMP.  Comparisons with the structures of NDT6 and 
Rcl10-12 revealed a structural basis, which was not obvious from sequence comparisons 
alone, by which NDT family members differentiate between ribosyl and 2!-
deoxyribosyl substrates.  The selectivity is attributed to a phenylalanine residue found 
in MilB and BcmB that is replaced by tyrosine in NDT and Rcl.  In support of this 
hypothesis, in vitro enzymatic activity assays showed that for both MilB and BcmB, 
mutation of the active site phenylalanine residue to tyrosine resulted in a reversal of 
substrate preference from CMP to dCMP.   
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Figure 2.1.  Natural products with cytosine precursors.  (A) Cytosine, or a cytosine 
derivative, is incorporated in the natural products mildiomycin, bacimethrin and 
blasticidin S.  (B) The first steps in their biosyntheses involve the enzymatic release of 
cytosine or hydroxymethylcytosine from a CMP precursor by a CMP hydrolase 
enzyme.   
 
Section 2.2. Materials and Methods 
Cloning, Expression, and Purification of MilB and BcmB. All cloning 
procedures followed standard DNA manipulation methods.  The S. rimofaciens 
ZJU5119!milB gene was commercially synthesized by DNA2.0 and bcmB was cloned 
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using genomic DNA from C. botulinum A str. ATCC 19397.  The milB and bcmB 
genes were inserted into pTHT, a modified pET-28 plasmid (Novagen) containing an 
N-terminal His6-tag and TEV protease recognition site.   All mutant plasmids were 
prepared at the Cornell Protein Production and Purification Facility by site-directed 
mutagenesis of the native gene following standard, PCR-based mutagenesis.15!
Escherichia coli B834(DE3), a methionine auxotrophic cell line, was 
transformed with the pTHT-milB wild-type (WT) plasmid.  E. coli BL21(DE3) cells 
were used to express all other proteins.  Starter cultures were grown from a single 
colony in 10 mL of sterile LB media containing 30 !g/mL kanamycin (LB-kan) at 37 
°C overnight with shaking.  Selenomethionine (SeMet)-containing MilB was prepared 
in 1.5 L- cultures in minimal media with 0.4% glucose, 1x MEM vitamin mix, 2 mM 
MgSO4, 0.1 mM CaCl2, 25 mg/L FeSO4, 20 mg/L all amino acids except methionine, 
and 50 mg/L of L-selenomethionine.  To remove any LB media during SeMet protein 
preparation the overnight culture was centrifuged at 1000g for 20 min before the cell 
pellet was collected and resuspended in minimal media.  The 1.5 L volume was then 
inoculated with 5 mL of starter culture and allowed to grow at 37 °C with shaking 
until reaching an OD600 of 0.6, at which point the incubator temperature was reduced.  
Once reaching an induction temperature of 15 °C and OD600 ~0.8, protein expression 
was initiated by inoculating the cultures with 0.5 mM isopropyl "-D-
thiogalactopyranoside.   After 18 h, cells were centrifuged at 2000g for 20 min, 
collected, and frozen at -20 °C for storage.  For native protein overexpression, 5 mL of 
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overnight culture was added directly to 1.5 L of LB-kan media.  The cells were then 
grown, collected and stored as described for the preparation of SeMet-MilB protein. 
After thawing and resuspending the cell pellet in 45 mL of lysis buffer (50 mM 
Tris, 300 mM NaCl, and 20 mM imidazole at a pH of 8.0), the cells were lysed on ice 
with two rounds of sonication.  The cell extract was centrifuged for 30 min at 40,000g 
at 4 °C after sonication.  The supernatant was then collected and loaded onto a 2 mL 
Ni-NTA column (Qiagen) preequilibrated with the lysis buffer.  The column was 
washed with 50 mL of lysis buffer to remove any nonspecifically bound contaminants.  
To elute the protein, the column was washed with elution buffer (50 mM TRIS, 300 
mM NaCl, and 250 mM imidazole at a final pH of 8.0).  The elution sample was 
collected and further purified using size exclusion chromatography (HiLoad Superdex 
200 PG; GE Healthcare).  The purification procedures for WT and mutant BcmB, WT 
and mutant MilB, and SeMet MilB all followed this protocol.  The native MilbWT 
polyhistidine-tag was removed for crystallization by incubation with TEV protease for 
12 h at 4 °C.  The sample was passed over a Ni-NTA column preequilibrated with 
lysis buffer and the flow-through volume containing MilB was collected.  The purity 
of the sample was analyzed by SDS-PAGE before concentration to ~20 mg/mL.  
Protein was buffer exchanged by overnight dialysis into storage buffer (SeMet MilB: 
50 mM Tris,  pH 8.5, 500 mM NaCl; WT MilB: 10 mM Tris, pH 8.0, 100 mM NaCl; 
BcmB: 10 mM Tris pH 8, 50 mM NaCl) before flash freezing with liquid nitrogen for 
storage at -80 °C. 
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Crystallization of MilB and BcmB.  The hanging-drop vapor diffusion method 
was used for crystallization of both MilB and BcmB.  After mixing equal volumes of 
protein sample and reservoir solution, the samples were equilibrated overnight at 18 
°C against a total reservoir volume of 500 µL.  Protein concentrations for 
crystallization were 10 mg/mL for MilB and 15 mg/mL for BcmB.  Initial 
crystallization conditions were determined using commercially available sparse matrix 
screens  (Hampton Research, Emerald Biosystems).   
SeMet-MilB crystals grew as hexagonal rods approximately 200 µm long and 
40 µm wide under the optimized crystallization condition of 8% PEG 1000, 0.1 M 
phosphate-citrate pH 4.2, and 0.2 M Li2SO4 after two days.  A second condition for 
MilB crystallization was found with the N-terminal polyhistidine tag removed.  Square 
rods 400 µm long by 20 µm wide crystallized after two days in 0.1 M Tris pH 7.5, 0.2 
M MgCl2, and 18% PEG 8000.  The ligand soaked into the crystals added using a 
solution containing the components of the reservoir solution supplemented with 10 
mM cytosine and 10 mM ribose 5-phosphate for 5 min before cryoprotection.   
BcmB crystals formed 200 µm by 150 µm plates with 10 µm thickness in 18% 
PEG MME 2000, 0.1 M phosphate-citrate pH 4.4, 0.01 M spermine, and 0.2 M 
(NH4)2SO4 after five days.   All crystals were cryoprotected with a solution consisting 
of their crystallization condition supplemented with 20% ethylene glycol before flash 
freezing with liquid nitrogen.   
Data Collection and Processing.  X-ray diffraction experiments were 
conducted at the Advanced Photon Source NE-CAT beamline 24-ID-C (Argonne 
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National Lab) using a Quantum315 detector (Area Detector Systems Corp.) using 
vitrified crystals.  A fluorescence scan was conducted to determine the data collection 
wavelength corresponding to the maximum f!! for the SeMet-MilB crystals.  All data 
collection runs used the oscillation method with 1.0° rotation per frame.  HKL2000 
was used for indexing, integrating and scaling the data.16  Data collection and 
processing statistics are listed in Table 1.   
Structure Determination, Model Building, and Refinement.  The crystal 
structure of MilB was solved by single-wavelength anomalous diffraction (SAD) 
using SeMet-MilB.  This crystals belong to space group P6222 with a Matthews 
coefficient of 2.1 Å3/Da and an estimated solvent content of 41%, assuming one 
protein chain per asymmetric unit.17  Initial phase calculation and model building were 
carried out using PHENIX AutoSol.18, 19  Subsequent model improvement was 
performed using COOT for manual manipulations and PHENIX.refine with default 
parameters for structure refinement.19, 20  Water molecules were added during later 
rounds of refinement in PHENIX and the final structure was analyzed using COOT 
and MolProbity.21  The structure of MilB complexed with CMP was determined in 
space group C2 with two protein chains per asymmetric unit.  Under this new 
condition, MilB also crystallized with a Matthews coefficient of 2.1 Å3/Da 
corresponding to 41% solvent content.  SKETCHER was used for ligand generation 
before placement into Fo ! Fc electron density.22  Model improvement was performed 
as described above. 
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BcmB crystallized in space group C2 with three chains per asymmetric unit 
and a Matthews number of 3.2 Å3/Da, corresponding to a solvent content of 
approximately 61%.   The structure of BcmB was determined using molecular 
replacement, with the newly solved MilB structure as the search model.23  MolRep 
placed three chains in the asymmetric unit and further model building and refinement 
was carried out using COOT and Refmac.20, 24  The three chains correspond to one 
dimer formed through noncrystallographic twofold symmetry and one dimer generated 
by crystallographic symmetry.  Several rounds of refinement using Refmac and 
PHENIX.refine resulted in a BcmB model with R-factor and Rfree values of 21.7% and 
24.2%, respectively.  Refinement statistics for SeMet-MilB, MilB-CMP and BcmB are 
summarized in Table 2.1. 
Analytical HPLC. Reaction mixtures were analyzed by reverse-phase HPLC on 
an Agilent 1200 HPLC system equipped with a quaternary pump and thermostatted 
autosampler (4 °C).  The stationary phase was a Supelcosil LC-18-T column (15 cm ! 
4.6 mm, 3 "m particles). The LC eluent (1 mL/min flow rate) consisted of a gradient 
of methanol and 6 mM N,N-dimethylhexylamine (DMHA) in water that was adjusted 
to pH 6.5 by addition of acetic acid.  In the analytical method the percentages of 
DMHA (D) and methanol (M) balanced with water at time t varied according to the 
following scheme: (t,M,D): (0,0,100), (2,10,80), (12,20,60), (14,65,10), (16,0,100), 
(21,0,100).  Chromatograms were detected using the absorbance at 270 nm. UV-Vis 
spectra of substrate and product peaks were also collected and assessed. 
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Table 2.1:  Summary of  MilB and BcmB data collection and refinement statistics. 
  SeMet MilB-SO4 MilB-CMP BcmB-PO4 
beamline APS 24-ID-C  APS 24-ID-C  APS 24-ID-C  
resolution (!) 1.95 1.55 2.99 
wavelength (!) 0.97918 0.97918 0.97918 
space group P6222  C2  C2 
a (!) 97.8 45.2 177.9 
b (!) 97.8 100.4 40.2 
c (!) 61.9 71.5 98 
! (°) 90.0 99.6 98.0 
Matthews coefficient  2.1 2.1 3.2 
% solvent  41 41 61 
mol/asu  1 2 3 
Measured reflections 137124 162974 54150 
Unique reflections 23697 44996 14604 
Average I/" 37.1 (5.3)a 25.1(3.6)  17.8 (4.7) 
Redundancy  5.7 (5.4)  3.6(3.6)  3.7(3.8) 
Completeness (%) 98 (97) 99.8 (100)  99.9(100) 
Rsym (%)b 5.4 (32.1) 5.7 (35.2)  10.0(34.2) 
No. of protein atoms 1164 2369 2700 
No. of ligand atoms 10 41 15 
No. of water atoms 96 196 10 
Reflections in working set 23686 42663 14582 
Reflections in test set 1168 2269 737 
R-factor/Rfree (%)c 20.6/25.2 19.9/22.7 20.7/23.9 
rms deviation from ideals    
bonds (Å) 0.007 0.006 0.015 
angles (°) 1.072 1.061 1.975 
average B factor for protein 
(Å2)  28.1 18.0 49.1 
average B factor for water (Å2)  34.1 25.6 54.5 
average B factor for ligand (Å2)  31.3 17.0 84.2 
Ramachandram plot    
most favored (%) 97.3 98.0 96.3 
allowed (%) 2.7 2.0 3.7 
disallowed (%) 0.0 0.0  0.0 "Values in parentheses are for the highest-resolution shell. #$%&'!(!""i | Ii # <!> | / " <!>, where <!> is the mean 
intensity of the N reflections with intensities Ii and common indices h,k,l. )Rwork = "hkl| |Fobs| # k |Fcal| | / "hkl |Fobs| 
where Fobs and Fcal are observed and calculated structure factors, respectively, calculated over all reflections used in 
the refinement.  Rfree, is similar to Rwork but calculated over a subset of reflections (5%) excluded from all stages of 
refinement. 
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Substrate Specificity for MilB and BcmB. Substrate specificity studies for MilB 
and MilB F17Y were carried out with adenosine 5!-monophosphate (AMP), CMP, 2!-
deoxycytidine 5!-monophosphate (dCMP), guanosine 5!-monophosphate (GMP), and 
inosine 5!-monophosphate (IMP) (Figure S2.1).  Experiments were designed based on 
the previously described assay conditions used for MilA/MilB 25.  In vitro enzymatic 
assays were prepared with a final volume of 50 "L. AMP, CMP, dCMP, GMP, or IMP 
(1 mM) were added to MilB WT or MilB F17Y (10 "M) in 50 mM Tris buffer, pH 7.5 
and then the samples were incubated at 37 °C for 3 h. Control samples omitting 
enzyme were also prepared.  Reactions were quenched by boiling at 100 °C for 5 min.  
Samples were diluted with DMHA, filtered using a 3 kDa MWCO membrane, and 
analyzed by HPLC as described above.  Reaction products were compared to 
commercially available standards that were analyzed under identical conditions.  
Substrate specificity studies for BcmB and BcmB F6Y were carried out with CMP and 
dCMP as described above.  
Kinetics for MilB and BcmB. Kinetic parameters were monitored based on 
cytosine production from CMP or dCMP for MilB WT, MilB F17Y, BcmB WT, and 
BcmB F6Y. Each enzyme was incubated with varying substrate concentrations (see 
Table S2.1) in 50 mM Tris, pH 7.5 for 30 min at 37 °C and then the reactions were 
quenched by boiling at 100 °C for 5 min. Samples were diluted with DMHA, filtered 
using a 3 kDa MWCO membrane, and analyzed by HPLC as described above. 
Reaction products were compared to commercially available standards that were 
analyzed under identical conditions. The product absorbance signal was measured by 
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integration (ChemStation, Agilent Technologies) and compared to cytosine standards 
of known concentration. Kinetic parameters were calculated using the Michaelis-
Menten function in KaleidaGraph 4.0 (Synergy Software). 
Figure 2. Preparation. All figure 2.s were prepared using PyMOL 26, 
ChemDraw (Cambridge Biosoft), KaleidaGraph 4.0 (Synergy Software), or Excel 
(Microsoft), and compiled in Photoshop (Adobe). 
Section 2.3. Results 
Structure of MilB.  MilB with bound SO4 contains one protomer per 
asymmetric unit; however, a dimer is formed by crystallographic twofold symmetry.  
The final model at 1.95 Å resolution contains residues 11-162 of the possible 170 
amino acid residues.  The protomer of MilB contains an !/" fold with a five-stranded 
parallel "-sheet with a strand order of 21345 (flavodoxin-like).  The "-sheet is flanked 
on both sides by !-helices in an asymmetric manner (Figure 2.2A and 2.2B).  Dimer 
formation occurs through interactions between helices !4, !5, and !6 of the two 
protomers with an interface area of 1170 Å2.    Size exclusion chromatography 
confirmed the dimeric state of MilB (data not shown), which is consistent with the 
quaternary structures of both NDT (trimer of dimers) and Rcl.   
The MilB/CMP complex also crystallizes with one dimer per asymmetric unit.  
The final model at 1.55 Å resolution contains residues 12-168 of chain A and residues 
10-162 of chain B.  Each protomer is occupied by one CMP molecule and the overall 
structure is essentially the same as that of the MilB/SO4 complex.  Each dimer features 
two equivalent active sites.   
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MilB Active Site.  The MilB active site is located at the C-terminal edge of the 
!-sheet, between helices "4 and "5 (Figure 2.2C).  All of the interactions necessary 
for substrate binding and catalysis are contained within a single MilB protomer, with 
no direct participation from the adjacent protomer.  The phosphate/sulfate binding 
pocket contains hydrogen bonding interactions with the Ser97 sidechain, the amide 
groups of Gly99, Arg23, and Phe22, and two well ordered water molecules (Figure 
2.2D).  Ordered water molecules occupy the rest of the active site in the MilB/SO4 
structure.   
 
Figure 2.2.  Structure of MilB.  (A) The MilB protomer structure adopts an overall 
"/!-twist fold, depicted with !-strands in green and "-helices in blue.  (B) The 
topology diagram of MilB with !-strands in light green and "-helices in light blue.  
(C) The dimeric structure of MilB with chain A in green and chain B in cyan and 
ligands bound in the active sites.  (D)  The active site phosphate-binding pocket is 
occupied by a sulfate ion in the MilB/SO4 complex. 
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The structure of the MilB/CMP complex provides the molecular details of the 
nucleobase and ribosyl binding sites (Figure 2.3).  The products of the CMP 
hydrolysis reaction, cytosine and ribose 5-phosphate, were soaked into the MilB 
crystals.  Continuous electron density is observed in the active site representing CMP, 
the product of the reverse reaction, yet our in vitro studies did not show significant 
formation of CMP upon incubation of MilB, cytosine, and ribose 5-phosphate (data 
not shown).  Thus, the presence of CMP in the MilB/CMP active site is believed to be 
an artifact of crystallization conditions.  Glu92 accepts a hydrogen bond from the 4-
amino group of the cytosine base and, if protonated, would donate a hydrogen bond to 
CMP N5.  Glu103 accepts hydrogen bonds from the CMP 2!- and 3!-hydroxyl groups.  
Additionally, the side chain of Asp78 is within hydrogen bonding distance of the 
cytosine O2.  Phe17 C4 is positioned 3.5 Å from the CMP 2!-oxygen in the MilB 
structure.  
Structure of BcmB.  BcmB crystallized in space group C2, with three protein 
chains in the asymmetric unit.  The structure of BcmB was determined to 3.0 Å 
resolution using the MilB structure (47% sequence identity) described above as the 
molecular replacement search model.  The protomeric structure of BcmB displays the 
same "/#-twist fold as MilB, with five parallel #-strands forming a parallel #-sheet 
flanked on either side by "-helices (Figures S2.2A and S2.2B).  The final BcmB 
model contains 120 amino acids in chain A, 123 in chain B, and 110 in chain C.  The 
missing regions include residues 11-20 and 110-113 in chain A, 11-21 and 112 in B, 
and 10-24, and 109-112 in C, which correspond to loop regions.  Missing residues 47- 
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Figure 2.3.  Substrate binding in MilB.  (A) MilB-CMP binding interactions 
represented in stick view.  (B)  Schematic diagram of the MilB active site with CMP 
bound.  
 
55, 48-56, and 46-58 in protomers A, B, and C, respectively, correspond to a short !-
helix and loop when aligned with MilB.      
Chains A and B form a dimer by twofold noncrystallographic symmetry.  The 
buried surface area at the interface is 1320 Å2.  Chain C forms a dimer with an 
equivalent chain C using crystallographic twofold symmetry.  The buried surface area 
of this interaction is 1210 Å2.  This small discrepancy between the A/B and C/C 
interface surfaces areas can be attributed to additional disordered regions in chain C.  
Residues 58 and 59 in A and B and residue 114 in chain A are present at the A/B 
dimer interface, but are disordered at the C/C dimer interface.  The oligomeric state of 
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BcmB observed in the crystal structure is supported by size exclusion chromatography 
results (data not shown) and closely resembles the dimer formed by MilB (Figure 
S2.2C). 
BcmB Active Site.  The active site of BcmB is similar to that of MilB.  Each 
active site contains a bound phosphate ion from the crystallization solution.  The 
phosphate makes hydrogen bonds with the side chain of Ser86 and the amide 
backbone of Gly88 in the phosphate-binding pocket (Figure S2.2D).  Based on 
structural comparison to MilB, the BcmB active site residues that participate in 
substrate binding include Asp67, Glu92, and Phe6 (Figure 2.4).  Glu41 falls in a 
disordered region in the BcmB crystal structure, but is expected to be equivalent to 
Glu62 in MilB on the basis of sequence alignment. 
 
Figure 2.4.  BcmB/PO4 and MilB/CMP active site comparison.  A stereoview of 
BcmB/PO4 and MilB/CMP active sites superimposed.  The active site residues of 
BcmB and MilB display a conserved architecture.  Glu41 is disordered in the BcmB 
structure but conserved in sequence with MilB Glu62. 
 
Kinetics and Substrate Specificity for MilB and BcmB. Initial studies 
determined the substrate specificity of MilB for cytosine containing nucleotides.1  
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MilB preferentially hydrolyzed CMP, but cytosine was also observed, to a lesser 
extent, from dCMP (Figure 2.5).  MilB showed little to no hydrolysis of purine 
containing substrates (Figure S2.1).  CMP or dCMP was incubated with MilB F17Y 
and the production of cytosine was monitored to measure N-glycosidase activity. MilB 
F17Y successfully cleaved dCMP but was no longer able to effectively hydrolyze 
CMP (Figure 2.5).  Similar studies were conducted for both BcmB wild type (WT) 
and the corresponding active site Phe mutant (F6Y).  As with MilB WT, BcmB WT 
can hydrolyze CMP and, to a lesser extent, dCMP (Table 2.2).  Conversely, BcmB 
F6Y hydrolyzed dCMP with a 2!-deoxyribosyl group, while showing only minor 
activity with CMP (Figure S2.3).  
Steady-state kinetic parameters were determined for MilB WT, MilB F17Y, 
BcmB WT, and BcmB F6Y using either CMP or dCMP as substrates (Table 2.2). The 
kcat/Km value for MilB WT with hmCMP was previously reported as 22.1 M-1s-1.1  The 
kcat/Km values observed for MilB WT hydrolysis of CMP or dCMP were of 5.2 M-1s-1 
and 1.1 M-1s-1, respectively.1 
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Figure 2.5.  Substrate specificity of MilB WT and MilB F17Y.  (A) When MilB WT is 
incubated with CMP a large peak representing free cytosine is observed.  For MilB 
F17Y incubated with CMP, little hydrolysis is observed.  (B)  The opposite effect is 
observed with dCMP as substrate.  MilB F17Y hydrolyzes dCMP producing free 
cytosine.  There is comparably less dCMP hydrolysis by MilB WT.  
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Table 2.2:  Summary of kinetic data 
Protein (Substrate) kcat (min-1) Km (mM) kcat/Km (M-1s-1) 
MilB WT (CMP) 1.19  (0.06) 3.8  (0.5) 5.2  (0.7) 
MilB WT (dCMP) 0.36  (0.02) 5.4  (0.8) 1.1  (0.2) 
MilB F17Y (CMP) 0.0126  (0.0003) 4.5  (0.4) 0.046  (0.004) 
MilB F17Y (dCMP) 7.6  (0.3) 1.2  (0.2) 100  (10) 
BcmB WT (CMP) 0.090 ( 0.003) 0.19  (0.02) 7.8  (0.9) 
BcmB WT (dCMP) 0.055  (0.001) 0.57  (0.05) 1.6  (0.1) 
BcmB F6Y (CMP) 0.0048  (0.0004) 0.9  (0.2) 0.09  (0.02) 
BcmB F6Y (dCMP) 0.081  (0.001) 0.042  (0.004) 32  (3) 
 
Section 2.4.  Discussion 
Structure Comparison.  MilB and BcmB both adopt an !/"-fold composed of 
five parallel "-strands forming a core "-sheet flanked on either side by several !-
helices.  This fold is highly conserved among the NDT superfamily enzymes.  A 
pairwise DALI comparison between the MilB and BcmB structures results in a Z-
score of 16.9 and rmsd of 1.7, confirming their highly conserved tertiary structure 
(Table 2.3).27  A DALI structure search against the PDB starting with MilB reveals 
structural homology to the known 2#-deoxyribosyltransferases and Rcl.  Though their 
sequence identities are relatively low (11-22%), the enzymes retain similar folds.  
Based on a Z-score of 15.5 with a rmsd value of 2.3Å, MilB has the highest structural 
similarity to R. norvegicus Rcl (PDB ID 4FYI).12  Similar rmsd values of 2.5 Å and 
2.9 Å are observed upon comparison of MilB to the Rcl solution structures with PDB 
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IDs 2KHZ11 and 2KLH,10, 11 respectively.  Several 2!-deoxyribosyltransferases, such 
as the Trypanosoma brucei30 and L. leichmannii 6, 28, 29 NDTs (PDB ID 2F2T and 
1F8X) and L. helveticus purine nucleoside 2!-deoxyribosyltransferase (PTD) (PDB ID 
1S2L)29 are also among the most homologous structures.  
  While the enzymes in the NDT superfamily maintain a similar tertiary 
structure, their oligomeric assembly is not fully conserved.  Both NDTs and PTD form 
a hexamer composed of a trimer of homodimers, while Rcl, MilB, and BcmB are 
observed to form only dimers.6, 11, 28  Comparison of the dimers reveals a conserved 
mode of dimerization (Figure 2.6).  Like many members of the NDT superfamily,10 
the interactions observed at the dimer interfaces in MilB and BcmB are mainly 
hydrophobic (>97%).  
Table 2.3:  Enzymes structurally similar to MilB  
Protein PDB ID  Z score rmsd  %identity 
No. aligned 
residues 
C. botulinum BcmB 4JEL 16.9 1.7 46 123 
R. norvegicus Rcl  4FYI 15.5 2.3 21 126 
R. norvegicus Rcl 
(NMR) 2KHZ 14 2.5 22 134 
R. norvegicus Rcl 
(NMR) 2KLH 13.7 2.9 21 131 
T. brucei NDT 2F2T 12 2.8 13 126 
L. helveticus PTD 1S2L 11.9 2.4 19 122 
L. leichmannii NDT 1F8X 10.6 2.8 11 123 
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Figure 2.6.  Comparison of enzyme dimerization.  MilB and BcmB are observed to be 
dimers.  Like MilB, BcmB and Rcl have a dimeric tertiary structure.  In their 
functional forms, NDT and PTD are hexamers composed from a trimer of dimers, in 
which the dimer (shown) is similar to that of MilB. 
 
Base Specificity. Structural analysis of MilB, BcmB, and related enzymes reveals the 
basis of their substrate specificities.  MilB shows specificity for the pyrimidine 
containing hmCMP or CMP substrates.  It does not hydrolyze the purine containing 
nucleotides, demonstrated by an inability to hydrolyze AMP, GMP, or IMP (Figure 
S2.1).  While highly specific for hmCMP or CMP, its relatives display variable 
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nucleobase specificity (Table 2.4).  NDT accepts all naturally occurring and some 
synthetic nucleosides, while PTD30 and Rcl7 are specific for purine containing 
nucleosides or nucleotides, respectively.  In the structure of MilB/CMP, the Glu62 
carboxylic group is positioned approximately 3 Å from the cytosine, forming 
hydrogen bonds with the cytosine N3 and 4-amine group (Figure 2.3).  Helix !3 (on 
which Glu62 is located), helix !4, and the loop region formed by residues 67-70 
shield the MilB active site.  As a result, MilB has a relatively compact substrate-
binding site that cannot accommodate the bulkier purine containing nucleotides.  
BcmB specificity is predicted to function similarly to MilB based on sequence and 
structural homology. 
Table 2.4:  Summary of NDT-superfamily enzymes 
Enzyme Preferred Base 5'-specificity 2'-specificity Acceptor/ Nucleophile 
MilB hydroxymethylcytosine/cytosine phosphate OH water 
BcmB hydroxymethylcytosine/cytosine phosphate OH water 
BlsM cytosine phosphate OH water 
Rcl purine phosphate H water 
NDT purine/pyrimidine OH H purine/ pyrimidine 
PTD purine OH H purine 
 
The carboxylic acid from the NDT C-terminal Tyr157" and Gln46 amine 
interacts with its substrate nucleobase.  NDT can accommodate a variety of 
nucleobases because of its flexibility in both accepting and donating hydrogen bonds.6  
Like NDT, PTD interacts with nucleobases via hydrogen bonds from the carboxylic 
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tail of the C-terminal tyrosine located in the active site.  PTD diverges from NDT, as 
there are no equivalent interactions to those provided by Gln46 in NDT.28   The 
complexed Rcl structures10-12 reveal a large nucleobase binding area with no specific 
enzyme-nucleobase interactions, allowing Rcl to accommodate a variety of 
nucleobases in its active site.  Because the Rcl active site is rather open, it is solvent 
accessible and favors the larger purine containing substrates that can aid in shielding 
the active site from the solvent.  As evidenced by the structures of MilB and other 
NDT superfamily members, their nucleobase specificities are derived from a 
combination of favorable enzyme-substrate hydrogen bonding interactions and active 
site accessibility.  
Specificity at the 5!-position.  The NDT family members differ in their 
substrate preference for either a hydroxl or phosphate group at the 5!-position (Table 
2.4).  The high-resolution MilB/CMP structure reveals key information about the 
enzyme-substrate binding interactions at the CMP 5!-position, including seven 
hydrogen bonds.  Two ordered water molecules each contribute one hydrogen bond, 
while Ser97 is hydrogen bonding distance from either of the two 5!-phosphate oxygen 
atoms.  While the active site serine residue observed in MilB is conserved in both 
BcmB and BlsM (Figure 2.7), the remaining interactions in the MilB phosphate-
binding pocket come from amide backbone groups and ordered water molecules.  The 
amide backbones of Phe22, Arg23, and Gly99 act as hydrogen bond donors, 
completing the phosphate-binding pocket (Figure 2.8A).  Although the identities of the 
backbone residues are not conserved in sequence, the phosphate ion in BcmB/PO4 is 
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observed in an analogous binding pocket to MilB (Figure 2.8B).  This pocket is also 
rich with hydrogen bond donors resulting in preference for phosphate groups at the 5!-
position. 
 
 
 
Figure 2.7.  Sequence alignment of enzymes containing the nucleoside 2!-
deoxyribosyltransferase motif.  Sequence comparison between MilB/BcmB and other 
family members reveals conservation of the key catalytic residues (arrows) but not of 
those conferring substrate-binding specificity.  The serine residue involved in 
phosphate binding is indicated with a star.   Phenylalanine and tyrosine residues 
known to be positioned in the active site are underlined.  Representative sequences for 
NDT from L. leichmannii and Rcl from R. norvegicus were used. 
 
A 5!-phosphate binding pocket utilized for nucleotide binding was also 
observed in Rcl.10-12  The structure of Rcl shows hydrogen bonding contacts between 
the GMP phosphate group and Ser17, Arg19, Ser87, and Ser117! (Figure 2.8B).  This 
motif is highly conserved in the sequences of 13 different species in Rcl.10  While 
MilB does not share this motif, the positively charged pocket is consistent with 
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preference for nucleotide monophosphate binding.  In NDTs and PTD, an aspartate 
residue plus either an asparagine or glutamine residue stabilizes nucleoside 5!-
hydroxyl groups, favoring nucleoside binding  (Figure 2.8C)6, 28 and preventing the 
binding of 5!-phosphate containing nucleotides preferred by MilB and BcmB.4   
Specificity at the 2!-position.  While MilB and BcmB contain the conserved 
NDT motif, their ability to hydrolyze the N-glycosidic bonds of ribosylnucleotides 
makes them unique from other enzymes in this class.  NDTs, PTD, and Rcl show no 
glycosidase activity towards ribosyl-containing substrates, which in some cases are 
inhibitory.9  Conversely, MilB and BcmB show higher activity towards substrates 
containing 2!-hydroxy groups (Table 2.2).  MilB and BcmB both have very low levels 
of activity for the hydrolysis of dCMP.  In the related Rcl and NDT structures, a 
tyrosine residue is observed near the substrate 2!-binding position (Figure 2.8).  Not 
obvious from sequence analysis alone, the structures of MilB and BcmB reveal a 
phenylalanine in the position equivalent to this tyrosine near the conserved catalytic 
glutamate (Figure 2.7).  Compared to Rcl or NDTs, this phenylalanine residue is the 
only residue near the 2!-binding position that differs in either MilB or BcmB.   
The identity of the active site phenylalanine or tyrosine residue proves to be 
important in differentiating between ribosyl or deoxyribosyl containing substrates by 
MilB and BcmB.  Structural studies of PTD,28 which has a tyrosine residue near the 
2!-binding position, suggested that ribosylated substrates form hydrogen bonds with 
the catalytic glutamate, rendering it unreactive.  This rational contradicts our findings 
in which MilB and BcmB react with ribosylated substrates, despite also showing 
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interactions between their catalytic glutamate and the substrate 2!-hydroxy group.  
When both a hydroxy containing substrate and active site tyrosine are present, the 
glutamate may be too constricted by hydrogen bonds to position itself for catalysis.  In 
the absence of an active site tyrosine, the catalytic glutamate is not restricted by the 
ribosylated substrate.  Rather, the ribosylated substrate may help orient the glutamate 
for catalysis. 
Acceptor/Nucleophile Binding Site.  Previous studies of NDT-superfamily 
members have explored the structural basis of nucleophile binding at the active site.  
In NDT, the interaction between Gln46 and the nucleobase positions the loop region, 
on which Gln46 is located, shielding the active site from solvent.28  Along with a 
hydrophobic binding pocket, this excludes water as a nucleophile.  After initial N-
glycosidic bond cleavage and release of the base, NDT binds the incoming acceptor 
base, positioning it for the second half of the NDT transferase reaction.  Due to more 
limited substrate-enzyme interactions in PTD, the corresponding loop region does not 
shield its active site28 and bulkier purine bases that shield the active site are favored 
over smaller pyrimidines, both as substrate and acceptor nucleobases.  Compared to 
NDT, Rcl has a longer loop region that does not shield the active site from solvent.  It 
also does not have any residues that specifically interact with and bind acceptor 
nucleobases.10-12  These structural features allow a water molecule to act as the final 
acceptor.    Because the MilB active site is shielded by "-helices, it is less solvent 
accessible as compared to PTD or Rcl.  Compared to NDT, the MilB active site is 
similarly shielded, but is not as hydrophobic.  As a result, an active site water 
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molecule is available to act as the final acceptor.  Accordingly, the MilB/CMP 
structure reveals a water molecule in the active site positioned 4.9 Å from the 1!-
ribosyl position.   
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Figure 2.8.  Active site comparison.  (A) Observed MilB interactions with CMP.  (B) 
Rcl active site with dGMP.  (C) NDT active site with deoxyadenosine. 
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Mechanism of Hydrolysis.  Previous studies showed that NDT family members 
catalyze transferase reactions utilizing a covalent enzyme-(deoxy)ribosyl 
intermediate.6, 9, 31  In the first half reaction the covalent intermediate forms between a 
glutamate side chain and C1! of the (deoxy)ribosyl group.  The second half reaction 
takes place after the purine/pyrimidine base is released and a nucleophile (either a 
different base or a water molecule) displaces the glutamate side chain.  The catalytic 
glutamate residue is absolutely conserved among the NDTs, Rcl, MilB, BcmB, and 
BlsM (Figure 2.8).  Based on this mechanism, Glu103 of MilB forms a covalent 
attachment to CMP at the ribosyl 1!-position in the first half of the hydrolysis reaction 
(Scheme 2.1).  Previous studies on xylanases, which utilize a glutmate/glycoside 
covalent intermediate in a hydrolysis reaction similar to that of MilB, showed that 
each half reaction proceeds through an oxocarbenium-like transition state.32  In the 
crystal structure of the MilB/CMP complex the glutamate oxygen atom is not correctly 
oriented for a strictly SN2 mechanism suggesting the formation of an oxocarbenium 
ion intermediate followed by trapping of the intermediate by Glu103.  The second half 
reaction, in which water displaces the glutamate side chain, likely proceeds through an 
oxocarbenium-like transition state.  In MilB, Asp78 is positioned to protonate the 
cytosine base leaving group and to activate a water molecule for the second half of the 
reaction.  This aspartate residue is conserved in MilB, BcmB, BlsM, and Rcl, also 
suggesting a conserved mechanism of hydrolysis. 
 
 
 
 !
46 
 
 
Scheme 2.1 
Reversal of Substrate Specificity.  Based on the structural data, we 
hypothesized that the active site phenylalanine is the key residue that confers 
specificity for either 2!-hydroxyl or 2!-deoxy groups.  In MilB, Phe17 C4 is 3.6 Å 
from the catalytic glutamate residue and 3.5 Å from the CMP 2!-hydroxyl group.   A 
tyrosine is at a position equivalent to MilB Phe17 in all previously solved structures of 
enzymes in the NDT superfamily, which prefer 2!-deoxy substrates (Figure 2.9).  MilB 
F17Y was constructed using site-directed mutagenesis and used to test if the 
phenylalanine to tyrosine change is sufficient to increase the efficiency of dCMP 
hydrolysis.  While MilB WT preferentially hydrolyzes CMP, with a five-fold lower 
efficiency towards dCMP, mutation of F17Y MilB resulted a 100-fold decrease in the 
hydrolysis of CMP and a 100-fold increase in the hydrolysis of dCMP, corresponding 
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to a >10,000-fold inversion of substrate specificity (Table 2.2).  A similar, but slightly 
smaller affect in substrate specificity was observed for BcmB. 
The largest change is seen in the preference of F17Y MilB for dCMP 
compared to CMP.  The value of kcat for WT MilB with CMP is about 3-fold larger 
than for that of dCMP.  For F17Y MilB, the value of kcat with dCMP is about 600-fold 
larger than for CMP.  For both WT and F17Y MilB, the KM values for both substrates 
are in a similar range with the value for F17Y MilB with dCMP being the lowest.  The 
value of kcat for WT BcmB with CMP is about 20-fold larger than for that of dCMP.  
For F6Y BcmB, the kcat with dCMP is about 20-fold larger than for CMP.  The KM 
values for WT and mutant BcmB show a larger range compared to those of MilB.  The 
lowest value is 0.042 mM for F6Y BcmB with dCMP and the highest value is 0.9 mM 
for WT BcmB with dCMP. 
 
 
Figure 2.9.  Active site comparison of MilB and NDT.  A stereoview active site 
comparison between MilB with CMP bound (green) and NDT with 5-methyl-2'-
deoxypseudouridine (5MD) (blue) reveals conserved positioning of the catalytic 
glutamate and aspartate residues.  Other key residues for substrate binding deviate 
between the two structures. 
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 In the structure of MilB/CMP, the CMP 2!-hydroxyl group interacts with the 
catalytic Glu103, orienting the molecule in the active site.  Based on the location of 
the Phe17 in MilB/CMP, the MilB F17Y Tyr17 hydroxyl group would be 3.1 Å from 
the 2!-hydroxyl group of bound CMP.   This may cause unfavorable interactions for 
CMP binding or cause electronic repulsions effecting hydrolysis by the catalytic 
glutamate residue.  The latter is consistent with the observed values of kcat, which is 
significantly enhanced while the KM values are in a similar range.  Additionally, WT 
MilB less efficiently hydrolyzes dCMP possibly because the 2!-group of dCMP cannot 
form any such hydrogen bonding interaction to orient it for catalysis.   Thus, WT MilB 
catalytic residues are best positioned for hydrolysis of CMP with the aid of the 2!-
hydroxyl group orienting CMP in the binding pocket.  These observations would also 
apply to WT and F6Y BcmB, which show patterns similar to WT and F17Y MilB in 
efficiency for hydrolysis of CMP and dCMP. 
Section 2.5. Supplementary Information 
Table S2.1.  Enzyme and substrate concentrations used in kinetics assays 
Protein (Substrate) [Enzyme] (!M) Substrate Range (mM) 
BcmB WT (CMP) 20 0.02 to 1.5 
BcmB WT (dCMP) 20 0.05 to 6 
BcmB F6Y (CMP) 80 0.1 to 6 
BcmB F6Y (dCMP) 10 or 20 0.03 to 1.2 
MilB WT (CMP) 10 or 20 0.05 to 18 
MilB WT (dCMP) 60 0.3 to 30 
MilB F17Y (CMP) 175 0.3 to 30 
MilB F17Y (dCMP) 1 0.1 to 8 
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Figure S2.1.  No hydrolysis of AMP, IMP, or GMP is observed when incubated with 
MilB or MilB F17Y. 
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Figure S2.2.  Structure of BcmB.  (A) The BcmB protomer adopts the same !/"-twist 
fold as MilB.  (B) The topology diagram of BcmB shows !-helices in purple and "-
strands in orange.  (C) The MilB dimer (blue) is shown superimposed with the BcmB 
dimer (green).  The two molecules have a rmsd of 1.7 and display a highly similar 
overall fold.  (D)  A phosphate ion is bound in the active site and makes hydrogen 
bond interactions with a serine residue and an amide group. 
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A) 
 
B) 
 
Figure S2.3.  Substrate specificity studies with BcmB.  A) BcmB WT with CMP and 
dCMP.  B) BcmB F6Y with CMP and dCMP 
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CHAPTER 3 
STRUCTURE OF CLOSTRIDIUM BOTULINUM THIAMINASE I-THIAMIN 
COMPLEX REVEALS BIOCHEMICAL DETAILS OF BINDING AND 
DEGRADATION 
Section 3.1. Introduction 
Thiamin (vitamin B1) is an essential vitamin in all living organisms.  Its active 
form, thiamin pyrophosphate, is a cofactor in many biological processes including 
carbohydrate metabolism and amino acid biosynthesis.  Most plants, fungi, and 
bacteria can synthesize thiamin, but animals must obtain it from their diets.  
Numerous investigations over the past sixty years provide a nearly complete 
understanding of thiamin biosynthesis,1 yet the physiological basis for its degradation 
and the fate of the breakdown products is still unknown.  Thiaminases catalyze the 
degradation of thiamin into its thiazole and pyrimidine components (Figure 3.1).  
These enzymes are found in a wide variety of organisms, including plants, fish, and 
bacteria.2-10  Consequently, ingestion of thiaminase containing foods by humans or 
other animals can cause symptoms of thiamin deficiency.11, 12  In humans, this 
deficiency can affect the cardiovascular system (wet beriberi) or nervous system (dry 
beriberi) with potentially fatal consequences.13, 14 
 
 
Reproduced with permission from Biochemistry, accepted. Early version of unpublished work 
copyright 2013 American Chemical Society 
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Figure 3.1.  Thiamin cleavage reaction catalyzed by the thiaminases.   Thiamin is 
degraded by thiaminase I or thiaminase II.  Thiaminase I utilizes a variety of 
molecules, whereas thiaminase II exclusively uses water, as the nucleophile. 
 
Biochemical analyses have established two distinct classes of thiaminases.  
Thiaminase I utilizes a variety of nucleophiles,15, 16 whereas thiaminase II exclusively 
utilizes water as the nucleophile.17  A crystal structure of the thiaminase I from 
Bacillus thiaminolyticus (Bt-thiaminase I) has been reported.18  Bt-thiaminase I is a 
monomer composed of two domains joined by three crossover segments and is 
structurally homologous to the group II periplasmic binding proteins (PBPs).18, 19  
PBPs bind small molecules and deliver them to ABC transporters for eventual uptake 
into the cytoplasm.  Structural studies reveal group II PBPs in an open conformation 
when no ligand is bound and in a closed conformation when a ligand is bound.19  Bt-
thiaminase I is a rare example of an enzyme in the group II PBP superfamily.  
Interestingly, THI5, the thiamin pyrimidine synthase in eukaryotes, is also a member 
of the group II PBP superfamily.20  Bt-thiaminase I is structurally similar to TbpA,21 
which is the PBP in many prokaryotes for thiamin, thiamin phosphate, and thiamin 
pyrophosphate, and THI5 is structurally similar to ThiY,20 which is the PBP in some 
prokaryotes for the thiamin degradation product formylaminopyrimidine.  These 
observations raise curiosities about the evolution of thiaminase I and its relationship 
to the PBPs.  Thiaminase II diverges in both structure and sequence from thiaminase 
I. 
Previous mechanistic and structural studies established that an active site 
cysteine residue is involved in thiaminase I catalysis.15, 16, 18  A crystal structure of Bt-
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thiaminase I with the mechanism-based, irreversible inhibitor, 4-amino-6-chloro-2, 5-
dimethylpyrimidine (ACDP), showed that the active site is located in a V-shaped 
cleft created between the two Bt-thiaminase I domains.  The active site location is 
structurally similar to the ligand binding site in the PBPs.  The active site cysteine 
residue is activated by a nearby glutamate residue to initiate the thiaminase I reaction.  
The activated cysteine first forms a covalent bond to the thiamin pyrimidine C6!.  
Subsequently, a nucleophile adds to the 5-methylene carbon of the pyrimidine moiety 
and the thiazole moiety is displaced.  Despite their highly divergent sequences and 
structures, thiaminase I and most thiaminase IIs utilize an activated cysteine residue 
to form a covalently bound intermediate.17, 18  
  Cb-thiaminase I is a 46.3 kDa enzyme from Clostridium botulinum.  The 
catalytic cysteine residue was predicted by sequence alignment with other thiaminase 
Is and mutated to generate a catalytically inactive Cb-thiaminase I (C143S).  C143S 
was co-crystallized with thiamin to obtain the C143S/thiamin complex reported here.  
This is the first structure of a thiaminase I/substrate complex and reveals atomic level 
details of thiamin binding prior to degradation.  This structure was used to identify the 
key amino acids involved in the Cb-thiaminase I reaction.   Kinetic studies of thiamin 
degradation by Cb –thiaminase I and six active site mutants determined the roles of 
these amino acids in thiamin degradation.  Together the C143S/thiamin structure and 
subsequent kinetic studies lead to a detailed Cb-thiaminase I mechanistic proposal.  
The physiological role of the thiaminases is explored once again with new insights 
from the atomic level interactions revealed by the C143S/thiamin complex. 
Section 3.2. Materials and Methods 
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Cloning, Overexpression and Purification of Cb-thiaminase I.  The thiaminase 
I gene, bcmE, was cloned from C. botulinum A str. ATCC 19397 genomic DNA.   
Standard DNA manipulation methods were used for all of the cloning procedures.  
The gene was inserted into pTHT, a modified pET-28 plasmid with an N-terminal His6 
tag, followed by a TEV protease cleavage site.  All active site mutants were obtained 
by site-directed mutagenesis of the native gene using standard, PCR-based 
mutagenesis.22 
 After DNA sequencing to verify plasmid accuracy, the plasmids were 
transformed into Escherichia coli BL21(DE3) cells and grown overnight at 37 °C on 
selective kanamycin (30 µg/mL) containing agar.   Starter cultures were then grown 
from a single colony.  A selected colony was placed in 10 mL sterile LB Lennox 
media containing 30 µg/mL kanamycin at 37 °C with shaking overnight.  The 
following day 5 mL of the overnight starter culture were added directly to 1.5 L 
volumes of sterile LB media.  Cells grew with shaking at 37 °C until reaching an 
OD600 of 0.6, at which point the incubator temperature was reduced to 15 °C.  Upon 
reaching an induction temperature of 15 °C and an OD600 of 0.8, protein 
overexpression was initiated by adding IPTG to the cultures with a final concentration 
of 0.5 mM IPTG.  Cells were harvested 18 h after induction of protein overexpression 
by centrifugation at 2000g for 20 min.  The cell pellet was collected and frozen at -20 
°C for storage. 
 The cell pellet was later thawed and resuspended in 45 mL of lysis buffer (50 
mM Tris-HCl, 300 mM NaCl, and 20 mM imidazole at pH 8.0) before lysing by 
sonication.  The lysed cell extract was centrifuged at 40,000g for 30 min at 4 °C.  The 
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supernatant was collected and loaded on to a 2 mL NiNTA column (Qiagen), 
preequilibrated with lysis buffer.  The column was then washed with 45 mL of lysis 
buffer to remove any nonspecifically bound contaminants from the column.  The 
protein was eluted from the column by passing 20 mL of elution buffer (50 mM Tris-
HCl, 300 mM NaCl, and 250 mM imidazole at a final pH of 8.0) through the column.  
The elution volume containing Cb-thiaminase I was collected.  This procedure was 
followed for purification of Cb-thiaminase I and all active site mutants. 
 To remove the His6 tag for crystallization, the purified C143S protein was 
incubated with TEV protease during dialysis into 3.5 L of 10 mM Tris HCl at pH 8.0, 
150 mM KCl and 1 mM dithiothreitol for 18 h at 4 °C, utilizing a ratio of 0.5 mg of 
TEV for every 10 mg of C143S.  The sample was then passed over a NiNTA column 
preequilibrated with lysis buffer.  The elution volume containing C143S with the His6 
tag removed was collected in the flow through.  Complete cleavage and purity were 
assessed by SDS-PAGE analysis.  The sample was buffer exchanged by overnight 
dialysis into 10 mM Tris-HCl at pH 8.0 and 150 mM KCl, then concentrated to 15 
mg/mL using a centrifugal filter device with a molecular weight cutoff of 10,000 Da.  
The purification process yielded approximately 3.5 mg protein per L of cell culture.  
The purified protein was aliquoted and flash frozen in liquid nitrogen for storage at -
80 °C.   
Co-crystallization of C143S/Thiamin.  For crystallization using the hanging 
drop vapor diffusion method, the protein was diluted with a solution of 10 mM Tris 
pH 8.0, 150 mM KCl and 10 mM thiamin with final concentrations of 7.5 mg/mL 
protein and 5 mM thiamin.  Equal volumes of protein and reservoir solutions were 
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mixed and equilibrated at 18 °C against a total volume of 500 µL well solution.  The 
initial crystallization condition was determined using the commercially available 
Wizard III sparse matrix screen (Emerald Biosystems).  The optimized crystallization 
conditions were 22% (w/v) polyethylene glycol 10,000, 0.1 M sodium citrate pH 4.4, 
and 2% (v/v) dioxane.  Needle-like C143S/thiamin crystals grew approximately 200 
µm long and 10-20 µm thick in three to five days.  Crystals were cryoprotected for 
data collection in a solution composed of the mother liquor supplemented with 20% 
(v/v) ethylene glycol. 
X-ray Data Collection and Processing.  X-ray diffraction experiments were 
conducted at APS NE-CAT beamline 24-ID-C (Argonne National Laboratory) using a 
Quantum 315 detector (Area Detector Systems Corp.) at a distance of 200 mm.  The 
oscillation method was used with 1.0º rotation per frame for 180º with cryocooling.  
Diffraction data was collected at wavelength of 0.97918 Å.  The NE-CAT in-house 
automated RAPD data collection and processing system, which utilizes XDS,23, 24 was 
used for indexing, integration, and scaling of the data.  Data collection and processing 
statistics are listed in Table 3.1.   
Structure Determination, Model Building, and Refinement.  The structure of 
C143S/thiamin was determined using the molecular replacement method.  The crystal 
belongs to space group P21 and contains two molecules per asymmetric unit 
corresponding to a Matthews coefficient25 of 1.96 Å3/Da and estimated solvent content 
of 37.4%.  The thiaminase I from B. thiaminolyticus (PDB ID: 2THI), with a sequence 
identity of 51% to C143S, was the molecular replacement model.  The automated 
search program MolRep26 positioned two chains in the asymmetric unit.  Iterative 
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rounds of model refinement were conducted using COOT27 for manual model building 
followed by refinement with PHENIX.refine28 using default parameters.  The thiamin 
substrate was added using PHENIX.ligandfit for placement into Fo ! Fc electron 
density. Water molecules were added during later rounds of refinement.  The quality 
of the structure was analyzed using MolProbity29 and COOT.27  Structure refinement 
converged with a final R-factor value of 18.7% and Rfree of 23.5%.  Complete 
refinement statistics are listed in Table 3.1.   
Determination of Kinetic Parameters.  Steady state kinetic analysis was 
performed for six Cb-thiaminase I mutant proteins selected based on the crystal 
structure of C143S/thiamin.  Cb-thiaminase I reactions were carried out in 100 mM 
potassium chloride, 713 mM "-mercaptoethanol, and 50 mM phosphate buffer at pH 
8.0.  All reactions were incubated at 25 °C except the E271Q mutant, which was 
measured at 37 °C due to low activity levels.  The reactions were initialized by the 
addition of enzyme to the reaction volume containing thiamin, with thiamin 
concentrations ranging from 100 µM to 10 mM.  Aliquots were taken from the 
reaction mixture after definite time intervals and quenched with 1 M HCl.  The aliquot 
was filtered through a 10,000 Da cutoff membrane to remove the enzyme and the 
filtrate was analyzed by HPLC. 
In the HPLC method, the ratio of 100 mM phosphate buffer at pH 6.6 (P) to methanol 
(M)/water mixture was varied over time in seconds (t).  The gradient was carried out 
following the scheme (t, M%, P%): (0, 0, 100), (5, 0, 90), (9, 15, 60), (14, 65, 15), (19, 
0, 100), (25, 0, 100).  HPLC peak areas were measured for varying concentrations of 
pure 4-methyl-5-thiazoleethanol.  A calibration curve relating peak area to 4-methyl-5-
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thiazoleethanol concentration was used to create a standard plot.  Peak areas of the 
product in the enzyme assays were measured and the concentrations calculated based 
on the standard plot.  The initial rates were calculated from plots of concentration 
versus time.  Initial rates were then plotted and fit to the Michaelis–Menten equation 
for calculation of kinetic parameters. 
Figure preparation.  All figures were prepared using PyMOL30 or ChemDraw 
(Cambridge Biosoft) and compiled in Photoshop (Adobe). 
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Table 3.1.  Summary of data collection and refinement statistics 
  C143S/Thiamin 
beamline APS 24-ID-C  
resolution (!) 2.18 
wavelength (!) 0.97918 
space group P21 
a (!) 63.5 
b (!) 36.3 
c (!) 156.8 
! (°) 91.4 
Matthews coefficient  1.96 
% solvent  37.4 
mol/asu  2 
Measured reflections 132,181 
Unique reflections 37,678 
Average I/" 16.3 (5.0)a 
Redundancy  3.4 (3.0) 
Completeness (%) 99 (92) 
Rsym (%)b 6.5 (29.4) 
No. of protein atoms 5643 
No. of ligand atoms 36 
No. of water atoms 496 
Reflections in working set 37.537 
Reflections in test set 1877 
R-factor/Rfree (%)c 18.7/23.5 
rms deviation from ideals  
bonds (Å) 0.010 
angles (°) 1.29 
average B factor for protein (Å2)  19.3 
average B factor for water (Å2)  26.8 
average B factor for ligand (Å2)  19.2 
Ramachandram plot  
most favored (%) 98.2 
allowed (%) 1.8 
disallowed (%) 0.0 
aValues in parentheses are for the highest-resolution shell. 
bRmerge = ##i | Ii $ <!> | / # <!>, where <!> is the mean intensity of the N reflections with intensities Ii and common indices h,k,l. 
cR-factor = #hkl| |Fobs| $ k |Fcal| | / #hkl |Fobs| where Fobs and Fcal are observed and calculated structure factors, respectively, calculated 
over all reflections used in the refinement.  Rfree, is similar to Rwork but calculated over a subset of reflections (5%) excluded from 
all stages of refinement. 
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Section 3.3. Results 
Overall structure of Cb-thiaminase I.  The structure of the C143S/thiamin 
complex, with two molecules per asymmetric unit, was determined at 2.2 Å resolution.  
The two molecules (A and B) make a total of 16 non-bonded interactions along an 
interface area of approximately 210 Å2, suggesting only crystal packing contacts.  Size 
exclusion chromatography (data not shown) predicted that Cb-thiaminase I is a 
monomer in solution.  This is also consistent with the oligomeric state of Bt-
thiaminase I.18  Of the 404 possible amino acids in the Cb-thiaminase I sequence, the 
structure contains residues 39-403, except for 313-314, of molecule A, and residues 
40-403 of molecule B, except for a missing loop area of residues 310-314, of chain B. 
Cb-thiaminase I is divided into two distinct domains (Figure 3.2).  The N-
terminal domain is composed of residues 39-120 and 297-384.  Residues 145-296 and 
385-403 form the C-terminal domain.  Both domains have a central !-sheet flanked on 
either side by "-helices with three crossover segments connecting the N- and C- 
domains.  Residues 144-145, 287-296, and 375-385 comprise the three domain linking 
regions.  The crossover segment formed by residues 287-296 connects !10 to !11 and 
the crossover segment created by residues 375-384 connects "14 and "15.  The third 
crossover connects !6 to !7 at residue 144.  The active site is located at a cleft between 
the two domains.   
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Figure 3.2.  Overall structure of C143S/Thiamin. 
(A) The ribbon diagram shows the !/" fold of C143S with !-helices depicted in blue 
and "-strands in green.  The two domains are composed of "-sheets flanked by !-
helices on both sides, connected by a central "-strand.  The thiamin-binding site is 
located in the central groove between the N- and C- terminal domains.  The 90° 
rotation shows the orientation of the thiamin molecule in the binding cleft.  (B) The 
topology diagram of C143S following the same coloring scheme as in (A). 
 
Cb-thiaminase I Active Site and Substrate Binding.  The structure of 
C143S/thiamin reveals the substrate binding site and atomic level details of binding 
interactions (Figure 3.3).  There is one thiamin molecule observed per protein 
molecule.  This cleft is approximately 17 Å deep, 15 Å long, and 12 Å wide.  Six 
tyrosine residues, Tyr46, Tyr48, Tyr80, Tyr252, Tyr269, and Tyr300, form the outer 
collar of the V-shaped cleft with the catalytic residues located at the bottom of the 
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cleft.  The catalytic cysteine residue Cys143, which is represented by Ser143, is 
located on !6. 
 Thiamin binds to the active site with a 108° angle between its pyrimidine C5! 
and thiazole N3.  The thiamin pyrimidine and thiazole moieties are approximately 
perpendicular with a dihedral angle of 85.9° between their two planes.  With torsion 
angles of "T= -10° (C5!-C7!-N3-C2) and "P= -93.6° (N3-C7!-C5!-C4!) the bound 
thiamin most closely matches the standard thiamin F-conformation.31 The pyrimidine 
portion of the thiamin is positioned towards the bottom of the V-shaped binding 
pocket.  Hydrogen bonds form between the thiamin N1! atom and the side chains of 
Ser143 and Glu271 (Figure 3.4).  The thiamin N3! atom is positioned 2.7 Å from the 
Asp302 carboxylate group and within hydrogen bond distance.  The 4!-amino group is 
within hydrogen bond distance of Asp302 (3.0 Å), Asp94 (2.9 Å) and Tyr46 (3.1 Å).  
The Tyr80 hydroxyl group is 3.5 Å from the positivity charged N3 atom and 2.7 Å 
from the Tyr46 hydroxyl group.  The thiazole group does not interact with the enzyme 
and is extended towards the top of the binding groove with the 5-hydroxyethyl group 
extended out toward the solvent region.   
Steady-state kinetics of Cb-thiaminase I WT and mutants.   Thiamin 
degradation by Cb-thiaminase I can be quantified using HPLC to analyze the reaction 
products.  Bt-thiaminase I WT catalyzes the thiaminase reaction with a turnover rate 
of 2.31 x 102 s-1 and a kcat/Km value of 5.10 x 105 M1s-1.  All activity was abolished by 
mutation of the catalytic cysteine in C143S.  The kinetic parameters for five other Cb-
thiaminase I active site mutants are reported in Table 3.2.   
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Figure 3.3. C143S/Thiamin active site interactions.  The stereodiagram displays active 
site residues near the thiamin-binding site with the thiamin molecule modeled into the 
final 2Fo-Fc electron density map contoured at 1!.   
 
 
 
 
 
 
 
 
 
 
Figure 3.4.  Thiamin binding in C143S.  The schematic representation of thiamin in 
the C143S active site displays the enzyme-substrate active site interactions.  All 
distance values given are in angstroms (Å). 
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Table 3.2.  Kinetic properties of thiaminase activity for Cb-thiaminase I WT and 
active site mutants 
Mutant kcat(s-1)  KM (M)  kcat/KM(M
-1s-1)  
WT (2.31 ±1.10) x 102  (4.52 ±0.51) x 10-4 5.10 x 105 
C143S 0 - - 
Y80F 1.07 ±0.12 (2.11±0.81) x 10-3 4.96 x 102 
D302N 8.14 ±0.74 (3.07±1.09) x 10-5 2.64 x 104 
E271Q (1.1 ±0.03) x 10-2 (7.47±1.25) x 10-5 1.50 x 102 
Y46F 6.09 ±0.384 x 101 (2.45±0.51) x 10-4 2.52 x 105 
D94N (2.3 ±0.2) x 102  (3.49±0.76) x 10-3 6.61 x 104  
 
Section 3.4. Discussion 
Structure Comparison.  Cb-thiaminase I is a group II PBP, as characterized by 
the arrangement of the three crossover segments characteristic of group II PBP 
members.  A DALI32 search against the PDB found proteins with high structural 
similarity to Cb-thiaminase I (Table 3.3).  Cb-thiaminase I has high structural 
homology to various PBPs despite shraring relatively low sequence identity with 
them.  The highest homology result found by the DALI search has a rmsd of 0.9 
between Cb-thiaminase I and Bt-thiaminase I (PDB ID 2THI) 32.  This extremely low 
rmsd value is expected, as they are orthologs and have a high 51% sequence identity. 
Accordingly, the structure of Bt-thiaminase I was the first to reveal that thiaminase Is 
have a PBP fold. 18, 21   
The structures of Cb-thiaminase I and Bt-thiaminase I reveal rare examples of 
proteins with a PBP fold that have an enzymatic function.  Most members of the PBP 
superfamily have evolved for various binding functions.  PBPs bind a variety of 
molecules including metals, vitamins, sugars, or amino acids 33.  This adaptability is 
attributed to the binding site location near the protein surface, which increases 
accessibility, and the conformational change that then closes off the active site upon 
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ligand binding. 33  This arrangement allows easy access to the protein active site for 
environmental ligands and new binding capabilities as mutation of the binding 
residues occurs.  The structural similarity of Cb-thiaminase I to PBPs suggests that 
thiaminase Is evolved from a PBP ancestor to accommodate thiamin and later 
developed a thiamin degrading function.   
Table 3.3. Enzymes structurally similar to Cb-thiaminase I 
Protein PDB ID 
Z 
score rmsd % identical 
no. of 
aligned 
residues 
Thiaminase I 2THI 57.2 0.9 51 361 
Maltose binding protein 1EU8 28.6 3.3 17 328 
ABC transporter binding, acbh 3OO6 26.2 3.4 11 390 
Periplasmic binding protein 2DFZ 25.2 3.4 16 323 
Iron binding protein 
Thiamin binding protein, TbpA 
1O7T 
2QRY 
21.2 
18.3 
3.0 
3.9 
10 
14 
287 
308 
 
 Conformational Changes.   As a result of their structural similarity, 
comparisons between the liganded Cb-thiaminase I and unliganded Bt-thiaminase I 
can be drawn.  Structural alignment of C143S/Thiamin, unliganded Bt-thiaminase I 
(2THI), and liganded Bt-thiaminase I/ACDP (4THI) reveals no hinged movement of 
the two domains upon thiamin binding (Figure 3.5A).  Both the liganded and 
unliganded forms appear to most closely resemble the closed conformation of group II 
PBPs.  Thiaminase Is may have lost the characteristic PBP conformational change as it 
evolved.  Because the PBPs display an open and closed conformation in order to bind, 
deliver, and release their substrates, for Cb-thiaminase I and Bt-thiaminase I this 
feature became unnecessary as they acquired a specialized enzymatic function. 
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Figure 3.5.  Comparison of C143S/Thiamin with Thiaminase I/ACDP structure from 
B. thiaminolyticus.  (A) C143S structure (gray) with thiamin (orange) superimposed 
with Bt-thiaminase I with covalently bound inhibitor (green, PDB ID: 4THI).  (B) 
Stereoview active site comparison between C143S and Bt-thiaminase I following the 
same coloring scheme as in (A).  The pyrimidine portion of thiamin from the 
C143S/thiamin complex is oriented perpendicular to the 2,5-dimethylpyrimidin-4-
ylamine (ADCP) inhibitor covalently bound to the active site cysteine in Bt-
thiaminase I. 
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Comparison to Thiamin Binding Sites in Other Proteins.  In addition to 
thiaminases, proteins that bind thiamin, or its mono- or diphosphorylated forms, 
include enzymes that use ThDP as a cofactor, thiamin biosynthetic enzymes, and 
thiamin transport proteins.   A common thiamin-binding motif is found in enzymes 
that utilize ThDP as a cofactor.  This 30-residue motif begins with –GDG- and 
concludes with –NN. ThDP binding is facilitated by phosphate binding interactions 
with a divalent metal, an aspartate, and an asparagine.1  When used a cofactor, ThDP 
binds in the V-conformation with !T! ± 90 and !p! 90°,2 with torsion angles defined 
as !T= C5"-C7"-N3-C2 and !P= N3-C7"-C5"-C4".  The alternative F- (!T! 0°, !P! ± 
90°) and S- (!T! ±100°, !P! ± 150°) thiamin conformations are less frequently 
observed in enzyme-substrate complexes although the F-conformation is the favored 
structure in solution.   The C143S/thiamin complex exhibits a rare enzyme-bound 
thiamin F-conformation.  Analysis of enzymes that bind thiamin or ThDP, but do not 
use it as a cofactor, reveals several other examples of structures with thiamin that is 
not in the common V-conformation.   
The structure of thiamin pyrophosphokinase (TPK) contains a bound thiamin 
in the F-conformation (!T= -6°, !P= -78°) (PDB ID: 1IG3).  This enzyme, which 
phosphorylates ThMP to form the active form ThDP, binds ThMP through multiple 
interactions.3   In addition to stacking interactions with a nearby tryptophan, the 
thiamin pyrimidine moiety makes hydrogen-bonding contacts between its 4"- amine 
with an aspartate and main chain carbonyl group, with an addition contact resulting 
between interaction between its N1" and a nearby serine.  The TPK substrate is further 
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anchored through a phosphate-binding pocket.  Similarly, ThMP kinase in complex 
with ThDP (PDB ID: 3C9T) displays the less common thiamin F-conformation (!T=  -
20°, !P= -64°).4  ThDP is bound in a cleft with stacking interactions between the 
thiazole and a nearby tryptophan.  In addition to phosphate binding pocket 
interactions, ThDP binding is further facilitated by 4"-amine hydrogen-bonding 
contacts with a glutamate residue.  While TPK, ThMP, and Cb-thiaminase I structures 
all contain F-conformation thiamins, their thiamin-binding motifs show little 
conservation.  Aside from all containing a common 4"-amine group anchored by either 
Glu or Asp, they share few other thiamin binding features. TPK and ThMP contain 
phosphate-binding pockets that can help facilitate binding of ThMP or ThDP.  In Cb-
thiaminase I, the phosphate end of ThMP or ThDP extends outward from the binding 
cleft toward the solvent.  ThMP in thiamin phosphate synthase (TPS) displays a non-
standard “cis” V-conformation (!T=  -95.6°, !P= -113°) (PDB ID: 2TPS).5  Like Cb-
thiaminase I, its pyrimidine is located at the bottom of its binding cleft.  There thiamin 
binding is aided by hydrogen bonding between its 4"-amine and N3" group with a Gln 
within an otherwise hydrophobic pyrimidine-binding pocket.   
 Despite sharing only 14% sequence identity, Cb-thiaminase I and E. coli 
thiamin binding protein, TbpA, have the group 2 PBP fold and have similar binding 
site locations; however, their thiamin binding motifs differ.  The TbpA ligand binding 
cleft is located in an analogous location between its two structural domains as in Cb-
thiaminase I.  In the reported structure, (PDB ID 2QRY)6, ThMP spans the length of 
the V-shaped cleft in an F- conformation (!T= 0°, !P= -83°).  TbpA binds ThMP by 
anchoring the phosphate group within a hydrogen bond rich pocket and sandwiching 
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the thiazole group between two tyrosine residues.  The ThMP pyrimidine interacts 
mainly through water-mediated hydrogen bonding with one hydrogen bond to a serine 
residue side chain.  In Cb-thiamianse I thiamin pyrimidine is buried in the bottom of 
cleft, with multiple hydrogen bonds and with C6! near Cys143, and the thiazole 
portion extending upward towards the solvent making only van der Waals interactions 
with the protein.  The similarities between thiamin binding modes between Cb-
thiaminase I and other non-cofactor thiamin binding proteins are limited, suggesting 
divergent evolution of their binding sites.  When used as a cofactor, the V-
conformation is necessary for its chemistry but sterically unfavorable.   It is 
unsurprising that in proteins that bind thiamin for non-cofactor functions the sterically 
favorable conformations are observed.  The ThMP riboswitch is another example of a 
thiamin binding mode in which ThMP binds in an alternative conformation (PDB ID: 
2HOM).7  This highly specific mRNA element binds ThMP in the S-conformation 
("T= -85°, "P= -173°), further supporting the observation that thiamin binding sites in 
these enzymes evolved to bind thiamin in a sterically favorable conformation, 
although not necessarily convergently. 
Cb-thiaminase I Thiamin Binding and Reaction Mechanism.  The 
C143S/thiamin structure served as a guide for investigation of the Cb-thiaminase I 
mechanism.   To bind thiamin, Asp302 interacts with the thiamin pyrimidine through 
multiple hydrogen bonds.  The D302N kcat value is approximately two orders of 
magnitude less than that of Cb-thiaminase I WT, implicating the importance of the 
anchoring interaction between the thiamin 4!-amino group and Asp302.   Other amino 
acids involved in thiamin binding include Tyr46, which hydrogen bonds with both 
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Tyr80 an the 4!-amino group, and mutational analysis of Y46F shows modest effects 
on both kcat and KM.  Tyr80 is within hydrogen bond distance to Tyr46 and mutation of 
Y80F mutation decreases the turnover rate more than 100 times.  The KM is also 
affected by this substitution, which is double for Y80F compared to WT, suggesting 
that Tyr80 may interact electrostatically with the thiazolium ion for binding. 
A detailed mechanistic proposal illustrates the complete series of steps 
involved in the reaction catalyzed by Cb-thiaminase I (Figure 3.6).  In the proposed 
mechanism, Glu271 deprotonates Cys143 to activate it for catalysis.   The 
deprotonated cysteine initiates the reaction by addition at the thiamin C6! position. 
The covalent addition by Cys143 is critical and the C143S mutant shows complete 
loss of thiaminase activity.  Demonstrating the importance of Glu271 for this step, the 
E271Q mutant kcat of 1.1 x 10-2 s-1 is significantly reduced compared to Cb-thiaminase 
WT with a kcat of 2.31 x 102 s-1.  After deprotonation by Glu271, Cys143 forms a 
covalent enzyme-substrate intermediate and the thiazole half acts as a leaving group 
with assistance from Asp94.   Structural and kinetic evidence supports the importance 
of Asp94 for catalysis, as well as thiamin binding.   Cb-thiaminase I efficiency is 
reduced by D94N mutation, with a kcat/KM value 10-fold lower than that of Cb-
thiaminase I WT.  Upon addition of the reaction nucleophile, Asp94 acts as a general 
acid to reprotonate the 4!-amino group, and rearrangement allows the covalent 
enzyme-substrate bond to break.   Cys143 is then reprotonated by Glu271 to 
regenerate the enzyme. 
 Alignment of thiaminase I sequences from several organisms shows 
conservation of residues equivalent to Cb-thiaminase I Tyr80, Asp94, Cys143, Glu271 
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and Asp302 (Figure 3.7).  In the proposed mechanism, these residues are critical for 
binding and catalysis as described.  The conservation of the catalytic cysteine and 
glutamate residues is consistent with the previously proposed mechanism.15, 18, 35   In 
addition, the importance of Asp94, Tyr80, and Asp302 for binding and catalysis is 
now established through structural evidence and kinetic data.   While Tyr46 mutation 
shows only modest effects on Cb-thiaminase I activity, Tyr46 is not fully conserved in 
sequence across these organisms.   This suggests that Tyr46 is involved in the thiamin-
binding hydrogen bond network, but is not essential for activity. 
Relationship to Thiaminase II.  TenA is the thiaminase II from Bacillus 
subtilus (PDB ID IYAK).  Like Cb-thiaminase I, TenA degrades thiamin into its 
pyrimidine and thiazole moieties.17  The monophosphorylated and diphosphorylated 
forms of thiamin (ThMP and ThDP) are not substrates for thiaminase IIs, whereas 
thiaminase Is can tolerate modification of the thiazole moiety, degrading thiamin and 
many thiamin derivatives.17, 34  Interestingly, thiaminase II is often clustered with the 
thiamin biosynthetic machinery.  This grouping of the biosynthetic and degradation 
enzymes was initially thought to be counterproductive.  It was later discovered that 
thiamin does not appear to be the preferred physiological substrate for thiaminase II.  
Rather, thiaminase II salvages base-degraded pyrimidine from the environment for 
incorporation into thiamin.36-38  
TenA adopts an overall !-fold that shows no homology to the Cb-thiaminase I 
structure.  The active site of TenA is buried and fairly inaccessible to potential 
nucleophiles, leading to exclusive use of water as the nucleophile.  This contrasts the 
Cb-thiaminase I two-domain !/"-fold and accessible active site location near the 
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surface of the enzyme, allowing a larger variety of nucleophiles to aid in catalysis.  
Despite their major structural differences, TenA and Cb-thiaminase share some active 
site features.  Both feature a catalytic cysteine and activating glutamate with an 
aspartate residue anchoring the pyrimidine.37  In the absence of a TenA structure with 
bound thiamin, the position of thiamin was previously predicted based on the structure 
of TenA with 4-amino-2-methyl-5-hydroxymethylpyrimidine (HMH) (PDB ID:  
1YAK).  The thiamin F-conformation observed in C143S/thiamin and the position of 
HMH were used to model thiamin into the TenA active site (Figure 3.8).  In this 
model, thiamin is anchored by interaction between Asp44 with N3!and the 4!-amino 
group, Glu205 and N1!, and Tyr163 and the 4!-amino group. The pyrimidine half of 
thiamin stacks above Tyr139 and the thiazole portion extends across the length of the 
binding pocket. It is further anchored by interactions between the thiazole 5-ethanol 
and Gln55 and Thr78.  The nearby catalytic cysteine, Cys135, is positioned nearby the 
site of covalent addition to thiamin C6!.   
 In TenA the glutamate residue is not close enough to directly deprotonate the 
cysteine and must act through two intermediate tyrosine residues, in contrast to Cb-
thiaminase, where Glu271 directly deprotonates cysteine.  Unlike TenA, there are no 
nearby tyrosine residues in Cb-thiaminase I that could possibly participate in a similar  
interaction.  While both thiaminase Is and IIs share a similar catalytic mechanism for 
thiamin degradation, their major structural differences and substrate preferences 
suggest that they evolved independently and may serve different physiological 
purposes.   
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The atomic level details of the Cb-thiaminase I enzyme-substrate complex 
provide a complete substrate binding model for comparison to functionally and 
structurally similar enzymes.  Structural comparisons suggest that thiaminase Is 
evolved from a PBP ancestor and later acquired a thiamin degradation function.  
Given that they can accept a variety of thiamin analogs, thiaminase Is may function in 
pyrimidine salvage, like thiaminase II.  An alternate hypothesis suggests that 
thiaminase I is used as a defense mechanism against other organisms, as observed in 
the toxic effect of consuming thiaminase I containing food.  It remains to be 
determined if thiaminase I containing organisms can utilize thiamin analogs for 
thiamin dependent reactions.  If so, depleting thiamin levels through thiaminase I 
activity would not be detrimental to the vitality of thiaminase I containing organisms. 
As identification of additional substrates and organisms containing thiaminase I genes 
continues, the structure of the Cb-thiaminase I co-crystallized with thiamin will assist 
in understanding their chemistry.   
 
Figure 3.6.  Mechanism of thiamin degradation by Cb-thiaminase I.   
The mechanism proposed for thiamin degradation by Cb-thiaminase I based on kinetic 
studies of Cb-thiaminase I mutants and structural data. 
 
 ! 80!
 
 
Figure 3.7.  Sequence alignment of thiaminase Is.  A multiple sequence alignment of 
Cb-thiaminase I, Bt-thiaminase I, and thiaminase I from additional organisms showing 
conservation of residues implicated for catalysis.  Residues corresponding to Cb-
thiaminase I Tyr80, Asp94, Cys143, Glu271, and Asp302 are conserved and 
highlighted with a star. 
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Figure 3.8. Comparison of thiamin binding in Thiaminase I and II.  (A) Thiamin 
binding interactions observed in C143S/Thiamin.  (B)  Model for thiamin binding in 
TenA based on C143S/Thiamin structure and TenA PDB ID: 2QCX. 
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 CHAPTER 4 
STRUCTURE-FUNCTION STUDIES ON CLOSTRIDIUM BOTULINUM 
BACIMETHRIN KINASE, BcmD 
Section 4.1. Introduction 
Thiamin (vitamin B1) is a cofactor in many essential biological processes.  
Numerous enzymes involved in primary metabolism rely on the active form, thiamin 
pyrophosphate (ThDP), to function.  As a result, severe thiamin deficiency causes 
illnesses such as beriberi or Wernicke-Korsakoff syndrome.  Humans are among those 
that obtain thiamin from dietary sources, while some organisms are capable of thiamin 
biosynthesis.  These biosynthetic routes differ between eukaryotes and bacteria, but 
both follow a two-branched path where 4-amino-5-hydroxymethyl-2-
methylpyrimidine pyrophosphate (HMP-PP) and thiazole phosphate carboxylate 
(THZ-P) are synthesized separately, then coupled by thiamin phosphate synthase to 
form thiamin monophosphate (ThMP).1  ThMP is then phosphorylated again to create 
ThDP (Figure  4.1A). 
 Bacimethrin (BCM), 4-amino-5-hydroxymethyl-2-methoxypyrimidine, is a 
structural homolog to HMP that acts as a thiamin antimetabolite.  It has previously 
been isolated from Bacillus magaterium and Streptomyces albus and is shown to be 
toxic to yeast and bacteria.2, 3  BCM toxicity is alleviated when the growth media is 
supplemented with HMP, thiamin, or pyridoxine.2-4  Initially thought to act as an 
inhibitor of thiamin biosynthesis, studies show that BCM acts as a substrate for 
thiamin biosynthetic enzymes,5 as BCM differs from HMP only by addition of a 
methoxy group at the 2-position.  In E. coli treated with BCM, the in vitro conversion 
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to MeOThDP is six times faster than ThDP synthesis when fed HMP.5  BCM hijacks 
the thiamin biosynthetic pathway, creating MeOThDP (Figure 1B) and diminished 
levels of ThDP.  Without this necessary cofactor, ThDP dependent reactions are 
halted, leading to cell death.5   
 
 
 
Figure 4.1. Routes to thiamin pyrophosphate (ThDP) and 2'-methoxythiamin 
pyrophosphate biosynthesis (MeOThDP).  A) Hydroxymethylpyrimidine 
pyrophosphate (HMP-PP) and thiazole phosphate carboxylate (THZ-P) are 
synthesized separately then ligated together and phosphorylated by thiamin 
biosynthetic machinery to produce ThDP.  B) Bacimethrin pyrophosphate (BCM-PP) 
is ligated to THZ-P by the thiamin biosynthesis enzymes to produce the thiamin 
analog, MeOThDP. 
 
The BCM biosynthetic pathway was recently characterized in Clostridium 
botulinum A ATCC 19397 (Begley Lab- manuscript in preparation).   In this pathway, 
a cytosine ribonucleotide serves as the precursor for BCM (Figure 4.2).  In contrast, 
bacterial thiamin biosynthesis utilizes a complex chemical reaction to convert 5-
aminoimidazole ribotide to HMP-P.6 HMP-P is then further phosphorylated by a 
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HMPP kinase to HMP-PP.1, 7  BcmD is annotated as the gene thiD-2 in C. botulinum.  
BcmD converts BCM to BCM-pyrophosphate (BCM-PP) through two sequential 
phosphorylations.  This reaction primes BCM to be shuttled into the thiamin 
biosynthetic pathway for production of MeOThDP.  BcmD is highly similar in 
sequence to known HMPP kinases, which are members of the ribokinase structural 
family.  In previous studies, the structure of HMPP kinase from Salmonella 
typhimurium (StHMPP kinase) has been solved with HMP bound in the active site 
(PDB ID: IJXI).8 Structural comparison of StHMPP kinase with other members of the 
ribokinases superfamily led to a model for ATP binding and subsequent HMP 
phosphorylation.  BcmD is expected to act in a similar manner and the structure of 
BcmD is of interest in understanding the substrate specificity of BCM biosynthetic 
enzymes.  
 
Figure 4.2.  Bacimethrin biosynthesis pathway.  A 5-hydroxymethyl is added to 
cytidine 5!-phosphate (CMP) by BcmA to create hydroxymethylCMP (hmCMP).  The 
hmCMP N-glycosidic bond is cleaved by BcmB and the hydroxymethylcytosine 
product is methylated at O2 by BcmC and SAM to produce bacimethrin (BCM).  In 
the final step, BCM is phosphorylated twice by BcmD to produce BCM-PP. 
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Functional studies show enzymatic synthesis of BCM when BcmA, BcmB, and 
BcmC are incubated with the necessary precursor molecules (Begley Lab- manuscript 
in preparation).  Incubation of BCM with BcmD and ATP and Mg2+ cofactors results 
in the depletion of ATP and BCM, with two new peaks observed when the products 
were analyzed by HPLC.   These two peaks represented molecules that are more polar 
than BCM, consistent with the formation of BCM-P and BCM-PP.  Treatment of the 
reaction products with alkaline phosphatase caused the products to revert back to 
BCM.  When ATP or BcmD was omitted from the reaction mixture, no consumption 
of BCM was observed.  BcmD showed similar activity toward HMP (Begley Lab- in 
preparation).  This activity reveals that BcmD is a kinase for both BCM and HMP.  In 
this study, the structure of BcmD was analyzed and compared to StHMPP kinase to 
determine if there is a structural basis for differentiating between these very similar 
pyrimidine substrates.  Here we report the structure of BcmD at 2.79 Å, compare it 
with structures of related ribokinases family members, and discuss the functional 
implications for its role in BCM-PP and MeOThDP biosynthesis.   
Section 4.2. Materials and Methods 
Cloning, Overexpression and Purification of BcmD.  The gene encoding 
BcmD, thiD-2, was cloned from the genomic DNA of C. botulinum A str. ATCC 
19397.   The gene was ligated into the pTHT vector, a modified pET-28 with an N-
terminal His6 tag followed by a TEV protease cleavage site.  Standard DNA 
manipulation methods were followed during all of the cloning procedures and the 
DNA was sequenced to verify plasmid accuracy.9  The plasmids were transformed into 
Escherichia coli BL21(DE3) cells and grown overnight at 37 °C on selective 
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kanamycin (30 µg/mL) containing agar.     For each starter culture, a single colony 
was selected and transferred to 10 mL sterile LB Lennox media with 30 µg/mL 
kanamycin at 37 °C with shaking overnight.  Approximately 18 h later, the overnight 
starter cultures were added directly to 1.5 L volumes of sterile LB media.  The cells 
were grown with shaking at 200 RPM in a 37 °C incubator until reaching an OD600 of 
0.6.  At this point the incubator temperature was reduced to 15 °C.  After reaching the 
induction temperature (15 °C) and an OD600 of 0.8, solid isopropyl-!-D-1-
thiogalactopyranoside (IPTG) was added to reach a final concentration of 0.5 mM 
IPTG in each 1.5 L flask.  The cells were shaken for approximately 18 h after addition 
of IPTG and then harvested by centrifugation at 2000g for 20 min.  The cell pellet was 
collected in 3 L aliquots and frozen at -20 °C for storage. 
 The cell pellet was later thawed and resuspended in 30 mL of lysis buffer (50 
mM Tris-HCl, 300 mM NaCl, and 20 mM imidazole at pH 8.0).  The resuspension 
was subjected to three rounds of sonication for 3 min on and 10 min off.  The lysed 
cell extract was next centrifuged at 40,000g for 30 min at 4 °C.  The supernatant was 
collected and loaded on to a preequilibrated 2 mL NiNTA column (Qiagen).  The 
column was washed with 50 mL of lysis buffer with a flow rate of 1 ml/min to remove 
any nonspecifically bound contaminants.  The protein was eluted from the column by 
passing 20 mL of elution buffer (50 mM Tris-HCl, 300 mM NaCl, and 250 mM 
imidazole at a final pH of 8.0) through the column.  The elution volume containing 
BcmD was collected.   
 BcmD purity was assessed by SDS-PAGE analysis.  The sample was buffer 
exchanged by overnight dialysis into 10 mM Tris-HCl at pH 7.5 and 150 mM KCl, 
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then concentrated to 14 mg/mL using a centrifugal filter device with a molecular 
weight cutoff of 10,000 Da.  The purification process yielded approximately 80 mg 
protein per L of cell culture.  The purified protein was aliquoted and flash frozen in 
liquid nitrogen for storage at -80 °C.   
Crystallization of BcmD.  The sitting drop vapor diffusion method was used 
for crystallization and the initial crystallization condition was determined using the 
commercially available Wizard II sparse matrix screen (Emerald Biosystems).    The 
protein solution was thawed on ice and equal volumes of protein and reservoir 
solutions were mixed and equilibrated at 22 °C against a total volume of 700 µL well 
solution.  The optimized crystallization conditions were 6-12% (w/v) polyethylene 
glycol 8,000, 0.1 M sodium/potassium phosphate pH 5.6, and 0.2 M NaCl.  Plate-like 
BcmD crystals grew approximately 150 µm by 100 µm in about two to three days.  
Crystals were cryoprotected for data collection in a solution composed of the mother 
liquor supplemented with 15% (v/v) glycerol. 
X-ray Data Collection and Processing.  X-ray diffraction experiments were 
conducted at APS NE-CAT beamline 24-ID-E (Argonne National Laboratory) using a 
Quantum 315 detector (Area Detector Systems Corp.) at a distance of 400 mm.  The 
oscillation method was used with 1.0º rotation per frame for 180º with cryocooling.  
Diffraction data was collected at wavelength of 0.97918 Å using 1 s exposures.  
HKL2000 was used for indexing, integration, and scaling of the data.10  Data 
collection and processing statistics are listed in Table 4.1.   
Structure Determination, Model Building, and Refinement.  The BcmD crystal 
belongs to space group P21 and contains two molecules per asymmetric unit. It has a  
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Table 4.1.  Summary of data collection and refinement statistics 
 BcmD 
beamline APS 24-ID-E 
resolution (!) 2.79 
wavelength (!) 0.97918 
space group P21 
a (!) 47.3 
b (!) 109.5 
c (!) 53.6 
! (°) 106.1 
Matthews coefficient 2.22 
% solvent 44.7 
mol/asu 2 
Measured reflections 48,203 
Unique reflections 13,017 
Average I/" 22.0 (3.9)a 
Redundancy 3.7 (3.6) 
Completeness (%) 100 (100) 
Rmerge (%)b 9.3 (38.6) 
Reflections in working set 37537 
Reflections in test set 1877 
R-factor (%) 21.5 
Rfree (%) 26.4 
rms deviation from ideals  
bonds (Å) 0.01 
angles (deg) 1.385 
average B factor for protein (Å3) 52.6 
Ramachandram plot  
most favored (%) 95.0 
allowed (%) 5.0 
disallowed (%) 0.0 
aValues in parentheses are for the highest-resolution shell. 
bRmerge = ##i | Ii $ <!> | / # <!>, where <!> is the mean intensity of the N reflections with intensities Ii and common indices h,k,l. 
cR-factor = #hkl| |Fobs| $ k |Fcal| | / #hkl |Fobs| where Fobs and Fcal are observed and calculated structure factors, respectively, calculated 
over all reflections used in the refinement.  Rfree, is similar to Rwork but calculated over a subset of reflections (5%) excluded from 
all stages of refinement. 
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Matthews coefficient11 of 2.22 Å3/Da and corresponding estimated solvent content of 
44.7%.  The structure of BcmD was determined by the molecular replacement method 
using StHMPP kinase with 42% sequence identity, as the search model (PDB ID: 
1JXH).  Two chains were positioned in the asymmetric unit by the automated search 
program MolRep.12 Iterative rounds of model building were conducted using COOT,13 
followed by refinement with RefMac514 in initial rounds and PHENIX.refine15 in final 
rounds. The quality of the final structure was analyzed using MolProbity16 and 
COOT.13 Structure refinement converged with a final R-factor value of 21.5% and 
Rfree of 26.4%.  Complete refinement statistics are available in Table 1.   
Section 4.3. Results 
 
 Overall Structure of BcmD.  The structure of BcmD was solved to 2.79 ! in 
the P21 space group, with two protein chains in the asymmetric unit.  The two chains, 
A and B, are related by 2-fold noncrystallographic symmetry and interact with an 
interface area from each chain of about 1390 !2 (Figure 4.3A).  The homodimer spans 
75 ! and is 41 ! wide by 33 ! deep.  At the dimer interface there are nine hydrogen 
bonds and 148 hydrophobic contacts.   The final model includes residues 2-239, with 
residues 117, 126, 178-180, and 197-208 in chain A and 109-11, 175-181, and 196-
208 in chain B disordered in the crystal structure.  The R-factor and R-free of the final 
BcmD model are 21.5% and 26.4%, respectively. 
Tertiary structure.  Each monomer forms an !-"-! three layer sandwich 
(Figure 4.3B).  The central "-sheet, with topology "2"1"5"6"7"8"9"10, is parallel, 
with the exception of "9 that runs anti-parallel to "8 and "10 (Figure 4.3C).  The !-
helices flank both sides of the "–sheet, with !1, !7, and !8 on one side and !2, !3, 
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!4, !5, and !6, on the other.  The remaining "-strands are part of an active-site flap in 
which residues 41 to 53 create the anti-parallel "3 and "4 strands that form a 
protective flap over the active site.  A second active site flap is created by a flexible 
loop composed of residues 106 to 114.   
 
 
 
Figure 4.3. Structure of BcmD.  A)  BcmD is a homodimer with !-helices depicted in 
blue and "-strands depicted in green. B) The BcmD monomer !-"-! three layer 
sandwich is shown with the same color scheme as in A. A core "-sheet is surround on 
either side by !-helices.  "-strands 3 and 4 form the active site binding flap.  C)  A 
topology diagram of BcmD displays the arrangement of the secondary structural 
elements  
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BcmD Active Site.  Each BcmD molecule contains two active sites, each self-
contained within the individual protomers.  Co-crystallization and soaking 
experiments were unsuccessful in obtaining a liganded BcmD structure.  The amino 
acids involved in substrate binding and catalysis are predicted from the superposition 
of BcmD with StHMPP kinase with bound HMP (PDB ID 1JXI) (Figure 4.4).  In this 
model, BcmD Glu42 makes a hydrogen bond with N4 of the pyrimidine substrate.  
The BcmD Met78 and Gly9 amino backbone groups bind a water molecule that 
hydrogen bonds with the pyrimidine N1.  The pyrimidine is also stabilized by water 
mediated hydrogen bonding by Asp21.  The ATP binding site is highly conserved in 
ribokinases.  While disordered in BcmD, the predictive anion binding GTGC motif 
common to this family is conserved in BcmD (residues 206-209) (Figure 4.5).  BcmD 
Asp103, Glu140, and backbone residues create a phosphate-binding pocket, with 
Lys173, Asp183, and Lys233 also positioned for favorable ATP binding interactions.   
 
 
 
Figure 4.4. Stereoview of BcmD active site aligned with StHMPP kinase/HMP and 
two sulfates.  The BcmD active site was identified by alignment with StHMPP kinase.  
All active site residues are conserved.  Gly208 and Gly206 are disordered in BcmD 
but conserved in sequence. 
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Figure 4.5.  BcmD/StHMPP kinase sequence alignment.  The residues of importance 
in StHMPP kinase activity are highlighted using the following scheme: purple circles 
(HMP binding), red squares (ATP binding), yellow star (Mg2+ coordination), green 
diamond (conserved active site residues).  All of the residues important for StHMPP 
kinase activity are conserved in BcmD. 
 
Section 4.4. Discussion 
Structure Comparison.  BcmD adopts an !-"-a sandwich fold with high 
structural similarity to known HMPP kinases and is classified as a member of the 
ribokinase superfamily based on its function and tertiary structure.  A DALI search of 
BcmD against the PDB reveals proteins with high structural homology (Table 4.2).  
The HMPP kinase from Thermus thermophilus (PDB ID 1UB0) has the highest 
structural homology, with a Z-score of 31.1 and rmsd of 1.6.  It shares 41% sequence 
identity with BcmD and also forms a dimer.  The DALI structural search also reveals 
the HMPP kinases from S. typhimurium, Bacillus subtilis, and yeast have similarly 
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high Z-scores and rmsd values as compared to BcmD.  As expected from previous 
structural studies of StHMPP kinase, BcmD also shares high structural homology to 
many known pyridoxine and ribokinases.   Although the sequence similarity decreases 
between BcmD and the pyridoxine and ribokinases as compared to the HMPP kinases, 
the overall structure remains conserved.  The structural homologs listed in Table 2 are 
all dimers in their biologically relevant states, further supporting the close relationship 
within this family of enzymes. 
BCM Binding Site.  The BcmD active site was identified by alignment with the 
StHMPP kinase structure containing HMP and sulfate in the active site.  The residues 
necessary for HMP binding in StHMPP kinase are conserved in BcmD such that BCM 
is presumed to bind BcmD similarly to HMP binding in StHMPP kinase (Figure 4).  
Residues that make hydrophobic contacts with HMP in StHMPP kinase are conserved 
in BcmD.  The BcmD binding pocket has room to accommodate the addition of the 2-
methoxy group in BCM, as BCM only differs from HMP at this position.  Preliminary 
studies suggest that BcmD may actually favor HMP as a substrate over BCM (Begley 
Lab- in preparation).   Any interactions that favor HMP over BCM are not clear from 
analysis of the active site binding pocket residues alone. 
ATP Binding and Kinase Reaction.  Members of the ribokinase family 
phosphorylate the hydroxymethyl group of a small molecule substrate.  In the absence 
of a StHMPP kinase/ATP structure, the binding and reaction mechanisms were 
deduced by comparison to other ribokinases structures. In this reaction, an inline 
displacement mechanism is utilized whereby an aspartate or cysteine activated water 
acts a base to deprotonates the HMP hydroxymethyl group.   The ATP co-substrate is 
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Table 4.2.  Summary of proteins structurally similar to BcmD 
Protein PDB ID Z score rmsd  
% 
identical 
no. of aligned 
residues 
T. thermophilus 
HMP Kinase 1UB0 31.1 1.6 41 212 
S. typhimurium HMP 
Kinase 1JXI 29.7 1.5 43 211 
B. subtilis HMP 
kinase 2I5B 29.1 2.1 43 218 
Yeast Thi20  3RM5 27.7 1.8 38 212 
E. coli pyridoxine 
kinase 2DDO 27.1 2.0 17 217 
Y. pestis 
pyridoxamine kinase 3PZS 25.5 2.1 17 220 
Human pyridoxal 
kinase 2YXU 25.0 2.0 19 218 
E. coli ribokinase 1RKA 19.3 2.5 18 204 
 
positioned in an ATP binding pocket near the small molecule hydroxymethyl acceptor 
group.  The ATP is highly coordinated by Mg2+ and Thr204.   Its !-phosphate is 
transferred to HMP to produce HMP-P.   During the reaction, the bound Mg2+ and the 
enzyme’s anion hole stabilize the transition state.  After the first phosphorylation, the 
ADP dissociates, then the HMP-P phosphate moves to an alternate binding location 
where it is stabilized by lysine, and a new ATP molecule binds similarly to the first.  
Finally, the second phosphorylation to produce HMP-PP occurs in a similar manner.  
Superposition of StHMPP kinase and BcmD shows conservation of the ATP and 
substrate binding sites.  Based on functional and structural similarity, this mechanism 
appears conserved in BcmD and by analogy, BcmD acts on BCM to produce BCM-
PP.   
Relationship to Ribokinases.  BcmD is classified as a member of the ribokinase 
family based on a conserved fold and active site architecture.   Ribokinases diverge in 
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the identity of the substrate, their substrate binding residues, and method of shielding 
the active site from the solvent.  Like StHMPP kinase, BcmD has two active site flaps 
formed by !-strands 3 and 4 and the loop region of residues 106-114 that close upon 
substrate binding.  In the unliganded BcmD model, this flap is in the “open” 
conformation (Figure 4.6).  The residues equivalent to this active site flap are ordered 
in the liganded StHMPP kinase revealing the “closed” state (PDB ID: 1JXI), but were 
disordered in its apo-structure (PDB ID: 1JXH).  The “open” structure of BcmD 
reveals a 10 ! movement of this flap upon substrate binding.  Members of the 
ribokinases family shield their bound substrates using structural features of varying 
complexity.8  The BcmD active site shielding mechanism is consistent with StHMPP 
kinase.  This method is distinct among members of this family, as the movement of 
the !-flap and loop region upon substrate binding appears to be one of the simplest 
shielding mechanisms.  Relatives such as ribokinases, adenosine kinase, and 
glucokinase evolved to contain insertions of additional secondary structural features 
that protect their active site.8   
Role in Bacimethrin Biosynthesis.    C. botulinum A str. ATCC 19397 contains 
two thiD genes, with 52% identity to each other.   In this C. botulinum strain, the thiD-
1 gene is clustered with a thiazole kinase and thiamin phosphate pyrophosphorylase, 
suggesting it is the HMPP kinase utilized for thiamin biosynthesis.  BcmD, encoded 
by thiD-2, is clustered in the newly established BCM biosynthesis pathway.  With 
high sequence similarity, overall structural homology, and nearly identical active site 
architecture, BcmD is very closely related to the thiamin biosynthesis HMPP kinase.  
BcmD has demonstrated substrate flexibility for either HMP or BCM, but it is not yet 
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clear whether BCM is a substrate for the HMPP kinase encoded by thiD-1.  In order 
for BCM to act as a toxin, it would be advantageous to the BCM producer if HMPP 
kinases phosphorylate BCM, allowing either BCM or BCM-PP to act as a toxin.   
BcmD may have evolved from a duplication event of the thiD gene, as its kinase 
activity prepares BCM to be shuttled into the thiamin biosynthesis pathway for 
production of the toxic ThDP analog, MeOThDP.  While the substrate preferences of 
BcmD for HMP and BCM is still being established, this preliminary finding and 
structural similarity establishes a close relationship between BcmD and the thiamin 
HMPP kinase.   
 
Figure 4.6.  HMPP kinase/BcmD active site binding flap movement upon substrate 
binding.  Purple  represents apo-BcmD and is superimposed on the structure of 
StHMPP kinase with HMP and sulfate bound (green).  The binding flap in apo-
StHMPP kinase is disordered (orange). 
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CHAPTER 5 
STRUCTURAL CHARACTERIZATION OF SsAziG, A STREPTOMYCES 
SAHACHIROI THIOESTERASE INVOLVED IN AZINOMYCIN B 
BIOSYNTHESIS 
Section 5.1. Introduction 
Azinomycin B (Figure 5.1A) is a complex natural product with antitumor 
activity isolated from Streptomyces sahachiroi and Steptomyces griseofuscus.1, 2  It is 
of interest to biochemists because of its unique structure, antitumor potential, and 
novel DNA crosslinking mechanism.  Azinomycin B and its analog, azinomycin A 
(Figure 5.1A), contain unusual and densely assembled functional groups.  Along with 
a naphthoate ring, epoxide, and 2-amino-1, 3-dicarbonyl groups, the azinomycins also 
contain an unprecedented aziridino[1,2a]pyrrolidine ring.  This unique architecture 
allows azinoymcin B to bind in the major groove of DNA and covalently crosslink to 
the N7 position of purine bases by electrophilic attack at its C10 and C21 positions.3  
Using this mechanism, azinomycin B binds in the major groove and creates DNA 
interstrand crosslinks with apparent sequence selectivity.4-7  Initial clinical studies on 
mice with leukemia show azinomycin B is effective at nanomolar concentrations and 
treatment with azinomycin B increases lifespan as compared to other DNA interstrand 
crosslinking drugs.2  These preliminary findings have led to drug discovery efforts to 
develop and evaluate azinomycin.8-10 
 The gene cluster responsible for azinomycin B biosynthesis in S. sahachiroi 
was recently identified.11  Sequence analysis revealed that the gene annotated as aziB 
likely encodes a polyketide synthase (PKS).  PKS megaenzymes generate polyketide 
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chains from acetyl-CoA and malonyl-CoA precursors.  These polyketide chains may 
then be modified and further condensed, either by the PKS itself or other partner 
enzymes.  Upon identification of the S. sahachiroi azi gene cluster, it was 
hypothesized the protein encoded by the aziB gene, SsAziB, is responsible for 
production of the naphthoic acid (NPA) moiety.  SsAziB is a 187 kDa protein and the 
only typical PKS gene in the azi gene cluster.  Sequence analysis reveals SsAziB 
contains ketosynthase, acyltransferase, dehydratase, ketoreductase, and acyl carrier 
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protein domains.  It was initially predicted that AziB iteratively condenses one acetyl-
CoA and five malonyl CoA molecules to form a hexaketide.  Subsequent 
intramolecular aldol condensations and dehydrations between C1/C9 and C5/C10 form 
the 5-methyl-NPA product later incorporated into azinomycin B (Figure 5.1B).   
 Initial studies reported that SsAziB is responsible and sufficient for the 
biosynthesis of 5-methyl-NPA.11, 12  More recent findings from the Watanabe group 
conflict with these reports.  Only 2-methylbenzoic acid forms when SsAziB is 
incubated with acetyl-CoA, malonyl-CoA, and NADPH (Watanabe Lab- manuscript 
in preparation).13  PKSs frequently contain thioesterase domains14 or have closely 
associate thioesterase partner proteins that catalyze the hydrolysis of a thioester 
metabolite in order to release an organic acid or CoA from intermediates in a stalled 
biosynthesis pathway.  When SsAziG, a thioesterase found in the S. sahachiroi azi 
gene cluster, is added to the reaction mixture, the mass of the reaction product is 
consistent with the production of 5-methyl-NPA.  The synthesis of a standard to 
confirm this product is underway.  To aid in functional characterization, we solved the 
X-ray crystal structure of SsAziG.  Further details about potential substrate binding 
interactions were revealed by the crystal structure of SsAziG complexed with the 
product analog, 3-hydroxy-2-NPA, and by structural comparison to known 
thioesterases.  These studies support the role of SsAziG in 5-methyl-NPA biosynthesis 
and lead to a proposed mechanistic and functional role for SsAziG in the azinomycin 
B pathway. 
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Section 5.2.  Materials and Methods 
SsAziG Cloning, Overexpression, and Purification.  The gene encoding 
SsAziG, aziG, was cloned into a pET-24a vector (Novagen) from genomic DNA from 
an azinomycin B producing strain of S. sahachiroi using standard DNA manipulation 
techniques.15   The DNA was then sequenced to verify plasmid accuracy.  The plasmid 
was transformed into chemically competent Escherichia coli BL21(DE3) cells.   The 
transformed cells were plated on selective kanamycin (30 µg/mL) cotaining agar and 
incubated at 37 °C overnight.  For each 1.5 L volume to be grown, a single colony was 
selected and transferred to 10 mL sterile LB Lennox media supplemented with 30 
µg/mL of kanamycin and shaken overnight at 37 °C.  After approximately 18 h, 10 mL 
of overnight starter culture was added directly to 1.5 L volumes of sterile LB.  The 
flasks were shaken at 200 RPM and 37 °C until the media reached an OD600 of 
approximately 0.6.  Upon reaching this OD600, the incubator temperature was turned 
down to 15 °C.  After the incubator reached the induction temperature of 15 °C and 
the media OD600 was approximately 0.8, solid isopropyl-!-D-1-
thiogalactopyranoside (IPTG) was added to reach a final concentration of 0.5 mM 
IPTG.   After induction of protein expression by addition of IPTG, the cells were 
incubated with shaking for approximately 18 h before harvesting.  The cells were 
harvested by centrifugation at 2000g for 15 min and stored in 3L aliquots frozen at -20 
°C until purification.   
 To purify the SsAziG protein, the 3 L cell pellet was thawed and resuspended 
in 45 mL of lysis buffer (50 mM Tris-HCl, 300 mM NaCl, and 20 mM imidazole at 
pH 7.5).  The resuspended cells were lysed on ice with three rounds of sonication for 3 
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min, with 10 min off after each round.  The lysed cell suspension was centrifuged at 
40,000g for 30 min at 4 °C.   The cleared lysate was decanted and loaded onto a 2 mL 
NiNTA column (Qiagen) preequilibrated with lysis buffer.  Following loading of the 
cleared lysate, the column was washed with 50 mL of lysis buffer at a flow rate of 1 
ml/min to remove non-specifically bound contaminants.   
To elute SsAziG, 20 mL of elution buffer (50 mM Tris-HCl, 300 mM NaCl, 
and 250 mM imidazole at a final pH of 7.5) was loaded on to the column and the 
volume containing SsAziG was collected.  SsAziG purity was assessed by SDS-PAGE 
gel electrophoresis.  The sample was buffer exchanged into 10 mM Tris-HCl, 50 mM 
NaCl at a pH of 7.5 by overnight dialysis and concentrated to 10 mg/ml using a 
centrifugal filter device with a molecular weight cut off of 3,000 Da.  The purified 
protein was aliquoted and flash frozen into liquid nitrogen for storage at -80 °C.  This 
purification process yielded approximately 25 mg of protein per L of purified cell 
culture.   
 Crystallization of SsAziG.   The hanging drop vapor diffusion method was used 
for crystallization.  In this method, the frozen protein aliquots were thawed on ice and 
equal volumes of protein and reservoir solution were mixed and equilibrated at 22 °C  
against a total volume of 500 µL well solution.  Using the commercially available 
sparse matrix Wizard screens (Emerald Biosystems), three crystallization conditions 
were identified.  Crystals were observed in Wizard I condition 13 (1.32 M ammonium 
sulfate and 0.1 M cacodylate pH 6.5), Wizard II condition 39 (0.1 M CAPS pH 10.5, 
0.2 M NaCl, and 20% PEG 8,000), and Wizard III condition 33 (1.6 M magnesium 
sulfate and 0.1 M MES pH 6.5).  Optimized crystals grew in 1.25 M ammonium 
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sulfate and 0.1 M cacodylate pH 6.0, 1.6 M magnesium sulfate and 0.1 M MES pH 
5.5, or 0.1 M CAPS pH 10.8, 0.2 M NaCl, and 14% PEG 8000.  In all three 
conditions, crystals with similar morphologies appeared overnight.  The crystals were 
square bipyramidal, 60 µm long, and about 40 µm in width at the center.  The crystals 
were cryprotected for data collection in a solution composed of their mother liquor 
supplemented with 15% (v/v) glycerol before flash freezing in liquid nitrogen.  For 
soaking experiments, the crystals were soaked with 10 mM 3-hydroxy-2-NPA for 5 
min before cryoprotection and flash freezing. 
X-ray Data Collection and Processing.  X-ray diffraction experiments were 
conducted at CHESS (Cornell High Energy Synchrotron Source) beamline F1 using a 
Q270 detector (Area Detector Systems Corp.) at a distance of 304.7 mm and 
wavelength of 0.91830 !.  The oscillation method was used with 1º rotation per frame 
for 90º with cryocooling and 10 s exposures. Crystals grown in all three conditions 
were tested for diffraction quality.  The data sets reported are for crystals grown in the 
ammonium sulfate containing condition.  Additional diffraction experiments on the 
ligand soaked crystals were conducted at APS NE-CAT beamline 24-ID-E (Argonne 
National Laboratory) using a Quantum 315 detector (Area Detector Systems Corp.) at 
a distance of 325 mm and wavelength of 0.97919 !.  The oscillation method was also 
used, with 1º rotation per frame for 70º with cryocooling and 1 s exposure time.  
HKL2000 was used for indexing, integration, and data scaling.16  Complete data 
collection and refinement statistics are listed in Table 1.  
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Table 5.1. AziG data collection and refinement statistics 
  AziG 
AziG/3-hydroxy-2-
NPA 
beamline CHESS F1 NE-CAT ID-E 
resolution (!) 2.15 2.4 
wavelength (!) 0.9183 0.97919 
space group I4122 I4122 
a (!) 68.5 68.2 
c (!) 139.6 139.7 
Matthews coefficient  2.73 2.71 
% solvent  54.9 54.6 
mol/asu  1 1 
Measured reflections 62888 36636 
Unique reflections 9373 6783 
Average I/! 37.3(5.8) 22.2(3.6) 
Redundancy  6.7(5.7) 5.4(5.5) 
Completeness (%) 99.5(100) 99.6(100) 
Rmerge (%)b 9.1(38.6) 9.4(35.6) 
No. of protein atoms 920 927 
No. of ligand atoms 0 14 
No. of water atoms 34 28 
Reflections in working 
set 
8883 6448 
Reflections in test set 446 323 
R-factor (%) 22.2 20.2 
Rfree (%) 26.6 25.0 
rms deviation from 
ideals 
  
bonds (Å) 0.007 0.008 
angles (deg) 1.17 1.101 
average B factor for 
protein (Å3)  
45.2 26.4 
Ramachandram plot   
most favored (%) 95.1 96.7 
allowed (%) 4.9 3.3 
disallowed (%) 0 0 "Values in parentheses are for the highest-resolution shell. #$%&'!(!""i | Ii # <!> | / " <!>, where <!> is the mean intensity of the N reflections with intensities Ii and common indices h,k,l. )Rwork = "hkl| |Fobs| # k |Fcal| | / "hkl |Fobs| where Fobs and Fcal are observed and calculated structure factors, respectively, calculated 
over all reflections used in the refinement.  Rfree, is similar to Rwork but calculated over a subset of reflections (5%) excluded from 
all stages of refinement. 
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Structure Determination, Model Building, and Refinement.  The SsAziG 
crystal belongs to space group I4122 and contains one promoter per asymmetric unit.  
It has a Matthew’s coefficient of 2.73 Å3/Da with corresponding solvent content of 
54.9%.17  The structure of SsAziG was determined using the molecular replacement 
method, with Mycobacterium tuberculosis thioesterase (PDB ID: 3S4K) as the model.  
The program Chainsaw was used to create a search model from 3S4K.18  Molecular 
replacement using this search model was conducted with MolRep.19  Iterative rounds 
of model building were conducting with COOT,20 with refinement using RefMac521 in 
initial rounds, and PHENIX.refine22 in final rounds.  The quality of the final structure 
was assessed using MolProbity.23  The final structure refinement was completed with 
an R-factor value of 22.2% and Rfree of 26.6%.  This structure was used as the model 
for refinement of the SsAziG/3-hydroxy-2-NPA structure.  PHENIX.elbow was used 
for ligand generation before placement into Fo ! Fc electron density.  Model 
improvement of the liganded structure was performed as described above.  Structure 
refinement for SsAziG/3-hydroxy-2-NPA converged with an R-factor of 20.2% and 
Rfree of 25.0%.  Complete refinement statistics for both structures are listed in Table 1.   
Section 5.3. Results 
 Overall Quality of SsAziG Model.  The structure of SsAziG was solved to 2.15 
! in the I4122 space group, with one protein chain in the asymmetric unit. The final 
model includes residues 11 to 134 and is approximately 40 ! long, and 20 ! by 25 ! 
wide.   There are 34 ordered water molecules in the final model. The R-factor and Rfree 
of the apo structure are 22.2% and 26.6%, respectively.   The SsAziG/3-hydroxy-2-
NPA crystal diffracted to 2.4 ! and also belonged to I4122 space group with one 
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protein chain in the asymmetric unit.  The complexed structure has 28 water molecules 
in the final structure and 14 ligand atoms.  Refinement converged with a R-factor of 
20.2% and Rfree of 25.0% for the SsAziG/3-hydroxy-2-NPA model. 
 SsAziG Tertiary Structure.  The SsAziG protomer displays the characteristic 
hotdog fold in which an antiparallel !-sheet surrounds a long "-helix on three sides 
(Figure 5.2).  The SsAziG antiparallel !-sheet, with strand order 
!1#!2$!4#!5$!6#!3$, twists around the 22 residues of "-helix 3.   Three additional 
"-helices 1, 2, and 4, are short secondary structural elements of only three to five 
amino acids found within the long loop regions of SsAziG.   
 
 
 
SsAziG Quaternary Structure.  The SsAziG tetramer is formed via 
crystallographic symmetry (Figure 5.3).  The tetramer is composed of four equivalent 
chains, with a total of four active sites.  Each active site requires residues contributed 
from two chains.  The largest interface area occurs between chains A and B.  Both 
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chains contribute 1,180 !2 of surface area to the interaction, with 26 interface residues 
from each.  Within this area there are 10 hydrogen bonds and 135 non-bonding 
interactions.  Chains C and D form an interface area equivalent to the AB interface.  
The AC interface and BD interface areas are equivalent.  They are 447 !2 in area and 
include six hydrogen bonds and 51 hydrophobic interactions, with 10 interface  
residues from each chain participating.  The AD and CB interfaces are 153 !2 in area 
and three interface residues from each chain form a total of seven hydrophobic  
interactions. 
 
 
 
Figure 5.3.  The biological tetramer formed by AziG.  The !-sheet of each monomer 
faces the core and the main "-helices face outward.   
 
 Substrate Binding Site.  The product analog, 3-hydroxy-2-NPA, is modeled 
into the final Fo-Fc electron density (Figure 5.4A).  The bound 3-hydroxy-2-NPA 
molecule reveals the active site locations at the AB and CD interfaces.  There are two 
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binding sites in each interface (Figure 5.4B), for four total active sites per molecule.  
In the SsAziG/3-hydroxy-2-NPA structure, the 3-hydroxy group forms a hydrogen 
bonding interaction with His48 and the NPA carboxy group forms a hydrogen bond 
with the amine group of Gly49, positioned at the positive dipole end of the long !-
helix 3 (Figure 5.4A).    3-hydroxy-2-NPA is found in a binding pocket formed at the 
AB or CD interface (Figure 5.4C).  This cavity is approximately 7 ! in diameter and 
20 ! deep. 
 
 
Figure 5.4.  AziG active site. A) Stereoview shows electron density for 3-hydroxy-2-
NPA and its interactions with the N-terminus of the central !-helix.  B) Each tetramer 
has four active site.  The location of two of the 3-hydroxy-2-NPA (yellow and orange) 
binding sites are drawn.  C)  The four equivalent 3-hydroxy-2-NPA binding pockets 
are created by the interface between chains A and B or C and D. 
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5-methyl-NPA Modeling.  Using manual modeling in COOT, the product of the 
SsAziB/SsAziG reaction, 5-methyl-NPA, was placed into the active site based on the 
location of 3-hydroxy-2-NPA.  The orientation and placement of the NPA ring 
remains nearly the same.  The model with 5-methyl-NPA with the most favorable 
binding interactions and no clashes was chosen (Figure 5.5).  In this model, the 5-
methyl-NPA carboxy group interacts with the amide group of Gly49, Ser61, and 
Gln42.   5-methyl-NPA is within 3.0 ! of the expected catalytic residue, Glu57.     
 
Figure 5.5.  A)  Model for 5-methyl-NPA binding and probable interactions.  B) 
Superposition of AziG and 5-methyl-NPA with Anthrobacter thioesterase with 4-
hydroxybenzoyl-CoA (PDB 1Q4U) reveals potential CoA binding mode. 
 
Section 5.4. Discussion 
 Structural Comparison.  SsAziG forms a long central !-helix surrounded by a 
six-stranded anti-parallel "-sheet and three small !-helices located within the 
connecting loop regions.  This tertiary arrangement is characterized as a hotdog fold, 
one of the two main structural families to which thioesterases belong.24  Thioesterases 
found in the hotdog fold superfamily are minimally a dimer, as residues from both 
subunits are necessary for catalysis.  While the quaternary structure varies among 
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hotdog fold thioesterases, SsAziG is a tetramer and most closely related to other 
thioesterases that also form tetramers.  A DALI structural search alignment against the 
PDB reveals proteins with tertiary structure closely related to SsAziG (Table 2).  
SsAziG is most highly structurally related to a putative esterase, Rv1847 from 
Mycobacterium tuberculosis (PDB ID: 3S4K), as revealed by a rmsd value of 0.9 
between the two structures.  SsAziG and Rv1847 share 50% sequence identity and 
both form tetramers.  The DALI search also reveals two structurally related 
thioesterases whose functions have been extensively studied.  Alignment with PaaI, a 
phenylacetic acid degradation protein from Thermus thermophilus (PDB ID: 1WLV), 
and 4-hydroxybenzoyl-CoA thioesterase, from Anthrobacter sp. SU (PDB ID: 1Q4S), 
results in RMSD values of 1.1 and 1.3, respectively.  These thioesterases both share 
31% sequence identity with SsAziG.  Despite their diverse physiological functions, the 
details of PaaI and 4-hydroxybenzoyl-CoA thioesterase mechanisms are informative in 
investigating the function and mechanism of SsAziG.  Finally, SsAziG shares 24% 
sequence identity with the human thioesterase superfamily member 2 (Them2, PDB 
ID: 2H4U) and their structure alignment has a rmsd value of 1.7.  Functional studies 
suggest Them2 is a fatty acyl-CoA thioesterase, important for fat metabolism.  While 
serving different physiological functions, the structural similarity of Them2 to SsAziG 
demonstrates the diversity of organisms that utilize hotdog fold thioesterases for 
various metabolic functions.   
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Table 5.2.  Summary of proteins structurally similar to SsAziG, as analyzed by DALI  
Protein PDB ID 
Z 
score rmsd 
% 
identical 
no. of 
aligned 
residues 
M. tuberculosis putative 
esterase, Rv1847 3S4K 22.8 0.9 50 121 
T. thermophilus PaaI, 
Phenylacetic acid degradation 
protein 1WLV 19.8 1.1 31 116 
Anthrobacter 4-
hydroxybenzoyl-CoA 
thioesterase 1Q4S 18.5 1.3 31 120 
H. sapiens thioesterase, 
them2 2H4U 17.9 1.7 24 117 
 
 Active Site.  SsAziG was co-crystallized with the product analog, 3-hydroxy-2-
NPA (Figure 5.4).  The !-helix dipole at the N-terminus of SsAziG !-helix 3 creates a 
positively charged environment at the bottom of the binding cavity.  This results in an 
electrostatically favorable binding environment for the negatively charged carboxy 
group of 5-methyl-NPA.  Based on the orientation of 3-hydroxy-2-NPA, the expected 
product, 5-methyl-NPA, was modeled into the active site binding cavity (Figure 5.5A).  
The location and orientation of 5-methyl-NPA is supported by alignment with 4-
hydroxybenzoyl-CoA thioesterase co-crystallized with 4-hydroxybenzyl CoA (PDB 
ID 1Q4U) (Figure 5.5B).  These structurally similar thioesterase enzymes have 
evolved in different organisms and function in specialized cellular roles, but their 
similarities reveal a fairly conserved mechanism.  As a result, the mechanism of 
SsAziG can be inferred based on structural comparison to these enzymes.  The 
residues important for catalysis in 4-hydroxybenzoyl-CoA thioesterase (Glu73*, 
Gly65, Gln58, Thr77*) are mostly conserved in the SsAziG active site.  The 
corresponding residues (Glu57*, Gly49, Gln42, and Ser61*) form the predicted 
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SsAziG catalytic machinery.  Glu57* (from chain B) acts as the nucleophile, while the 
amide groups from Gly49* and Gln42 aid in transition state stabilization via hydrogen 
bond formation with the thioester moiety (Figure 5.6).  Whereas Thr77* orients a 
water molecule for nucleophilic attack in 4-hydroxybenzyl-CoA thioesterase, SsAziG 
Ser61* is positioned to act similarly.   
 Substrate Binding.  In addition to the catalytic residues, several other residues 
are predicted to aid in 5-methyl-NPA-CoA substrate binding.  Many residues 
important for CoA binding in 4-hydroxbenzyl-CoA thioesterase are conserved in 
SsAziG.  In the structure of SsAziG, which was crystallized in ammonium sulfate, a 
sulfate ion occupies the predicted CoA phosphate-binding site.  Additional CoA 
binding interactions come from SsAziG His102** (from chain C); positioned to 
interact with the negatively charged CoA nucleotide phosphate group (Figure 5.5B).  
The amide backbone groups of Thr106** and Glu107** also create favorable CoA 
binding interactions.  Two arginine residues aid in binding the phosphate group in the 
4-hydroxybenzyl-CoA thioesterase structure.  Comparably, SsAziG Arg133 is 
structurally conserved in the C-terminal loop and could also aid in stabilizing and 
binding the negatively charged phosphate portion of 5-methyl-NPA-CoA.   
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 Proposed Mechanism.  Through structural comparisons with known 
thioesterases, a probable mechanism is hypothesized (Figure 5.6).  Throughout the 
reaction, Gly49 forms a hydrogen bond to the NPA carboxy group to anchor it during 
catalysis.  In this model, Glu57* acts as the active site nucleophile and transfers the 
intermediate NPA moiety from CoA to the enzyme.  Subsequently, a water molecule 
oriented by Ser61* for nucleophilic attack at the carbon of the carboxy-enzyme 
intermediate.  In concert, the bond between the catalytic Glu57* and the substrate is 
broken when the hydroxyl group is added.  The thioesterase reaction is then complete 
and the proposed product, 5-methyl-NPA can then be released.   
 Functional Implications.  The structure of SsAziG crystallized with 3-hydroxy-
2-NPA supports its function as the thioesterase involved in synthesis of the 
azinomycin B NPA moiety.  PKSs are able to catalyze the polymerization of 
polyketides by tethering the growing chain to a CoA arm and transferring the substrate 
to various catalytic domains.  The final step in the biosynthesis of the polyketide 
product is to release it from the CoA anchor, by thioester bond cleavage.  In the case 
of azinomycin B 5-methyl-NPA biosynthesis, AziB catalyzes the growth and 
condensation of 5-methyl-NPA moiety, but a thioesterase is necessary for its release.  
Lacking a thioesterase domain, AziB utilizes SsAziG for this final step.  Previous 
studies that attribute AziB to complete biosynthesis of 5-methyl-NPA were conducted 
in vivo in a heterologous host.  This may have led to nonspecific activity from an 
unidentified host thioesterase that released the NTA moiety from AziG.  Alternatively, 
non-enzymatic hydrolysis is also a possible explaination for this observation. 
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 Efforts to capture an AziB-AziG complex using crosslinking studies, size 
exclusion chromatography, and crystallography were so far unsuccessful.  The 
interaction between these two enzymes may be transient or require additional 
components.  Nevertheless, the role of SsAziG in 5-methyl-NPA biosynthesis is 
supported by both these structural studies and recent biochemical evidence.  Future 
efforts to crystallize and characterize AziB will shed more light on its mechanism for 
polyketide chain growth, shuttling of intermediates between different domains, and 
interactions with AziG. 
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CHAPTER 6 
SUMMARY 
 Protein X-ray crystallography is a powerful tool for determining the structural 
details of macromolecules at atomic resolution.  Obtaining an enzyme crystal structure 
can provide a multitude of information.  From a mechanistic enzymology prospective 
for example, the structure is valuable for identifying the enzyme active site.  Structures 
determined in the presence of substrates, products, or inhibitors are often critical in 
obtaining a mechanistic understanding of the enzymatic reaction.  Once the active site 
residues are identified, mutant kinetic studies are frequently conducted to confirm the 
role of individual residues in catalysis.  These biochemical studies compliment the 
structural findings and can lead to a proposed mechanism by which the enzyme 
catalyses its reaction.  This structure-function approach is especially useful when there 
is more than one plausible mechanism, or the mechanism is completely unknown.  
Other potential applications for X-ray crystallographic studies are immense.  In 
addition to mechanistic studies, X-ray crystallography is frequently used to understand 
protein-protein interactions, discover conformational changes, and help explain 
enzyme function.1   
The preceding studies used X-ray crystallography to study enzymes that 
catalyze reactions in bacterial metabolic pathways.  The metabolites of interest are 
either necessary for cell viability, as introduced in Chapters Two and Three on 
nucleotide and thiamin metabolism, or are used by the cell for some biochemical 
purpose, as discussed in Chapters Four and Five on bacimethrin and azinomycin B 
synthesis.  Understanding the basic biochemistry and selectivity of the processes by 
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which these metabolites are formed and degraded enriches our understanding of cell 
biology and chemistry.  Additionally, knowing the exact position of each atom in an 
enzyme enables exploration of mechanistic possibilities. 
 Novel structural details revealed the basis of substrate preference by NDT 
family members at the substrate 2!-position.  Introduced in Chapter Two, MilB is the 
CMP hydrolase involved in the early steps of biosynthesis of the commercially 
available antifungal compound, mildiomycin.2  Also discussed in Chapter Two is 
BcmB from the BCM biosynthetic pathway.  BcmB is closely related in sequence, 
function, and structure to MilB.  These two enzymes are classified in the NDT 
superfamily, whose members catalyze N-glycosidic bond cleavage of 2!-
deoxynucleosides via a covalent 2-deoxyribosyl-enzyme intermediate.3  Conservation 
of key active site residues suggested that members of the NDT superfamily share a 
common mechanism; however, the enzymes noticeably differ in their substrate 
preferences.   Substrates vary in the type of nucleobase, the presence or absence of a 
2!-hydroxyl group, and the presence or absence of a 5!-phosphate group.  We 
determined the structures of MilB and BcmB and compared them to previously 
determined structures of the NDT superfamily members:  NDT, PTD, and Rcl.3-6  The 
comparisons reveal how these enzymes differentiate between ribosyl and deoxyribosyl 
nucleotides or nucleosides, and among different nucleobases.  The structures of BcmB 
and the MilB-CMP complex reveal the presence of an active site phenylalanine near 
the substrate 2!-binding position.  Whereas MilB and BcmB prefer substrates 
containing 2!-ribosyl groups and have a phenylalanine positioned in the active site, 
NDT family members with preference for 2!-deoxyribosyl groups have a tyrosine 
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residue equivalently positioned.   This difference was not obvious from sequence 
comparisons alone.  Further studies show that this phenylalanine is critical for MilB 
and BcmB specificity towards CMP, and mutation of this phenylalanine residue to 
tyrosine results in a 1000-fold reversal of substrate specificity from its 2!-ribosyl 
containing substrate, CMP, to the 2!-deoxy containing analog, dCMP.  This novel 
finding is especially important in understanding the substrate specificity of NDT 
family members.  Commercially, NDT is exploited for enzymatic generation of 
nucleosides and this finding provides a potential basis for engineering NDT specificity 
at the 2!-position. 
Thiamin metabolism is another area of biochemistry that presents interesting 
biochemical and physiological questions.  The recent identification of the C. 
botulinum BCM biosynthesis pathway added to the interest in this area.  The genes 
encoding the enzymes responsible for biosynthesis of BCM, a thiamin antimetabolite, 
are clustered with a thiaminase I.   The physiological role of thiaminase I is a long 
standing mystery in thiamin biochemistry.  Thiaminase Is degrade thiamin into its 
pyrimidine and thiazole derived moieties.   The 2.2 Å resolution X-ray crystal 
structure of the catalytically inactive Cb-thiaminase I C143S mutant cocrystallized 
with thiamin provides the first structure of a thiaminase I with bound substrate.  The 
C143S/thiamin complex reveals the atomic level details of thiamin orientation upon 
binding to Cb-thiaminase I.  This structure was critical for the identification of active 
site residues involved in substrate binding and catalysis.  The specific roles of each 
active site residue was elucidated through site directed mutagenesis and kinetic 
studies, leading to a detailed mechanism for Cb-thiaminase I.  In this mechanism, a 
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catalytic cysteine is deprotonated by a nearby glutamate.  The cysteine initiates 
thiaminase activity by nucleophilic attack at the thiamin C6!.  The C143S/thiamin 
structure also brought attention to the role of the active site Asp94 and Tyr80 in 
substrate binding.   Kinetic assays established the role of these two active site amino 
acids in the expulsion of the thiazole moiety.  Cb-thiaminase I is also a rare example 
of an enzyme belonging to the periplasmic binding protein (PBP) superfamily.  
Structural analyses reveal similarities and differences between Cb-thiaminase I and 
PBPs.  Thiaminase I lacks the characteristic PBP “open” and “closed” conformational 
change upon substrate binding.  The structure of Cb-thiaminase I was also compared 
to the biochemically similar, but structurally and functionally unique, thiaminase II.  
This comparison revealed the two classes of thiaminases utilize distinct thiamin 
binding modes and are likely not closely related.  These structural and mechanistic 
studies support and expand upon the previous mechanistic and evolutionary 
understanding of thiaminase I. 
 Natural product biosynthesis pathways have evolved to create intricate 
chemical structures that intrigue scientists due to their novel chemistry and 
biochemical mechanisms.  While BCM is a fairly chemically simple, it is a 
physiologically puzzling natural product that acts as a thiamin antimetabolite.  It has 
been isolated from several prokaryotic organisms7, 8 and the BCM biosynthetic gene 
cluster in C. botulinum was recently identified.  First, BcmA adds a hydroxymethyl 
group to the CMP cytosine subsequent N-glycosidic bond cleavage by BcmB then 
frees hydroxymethylcytosine.  In Chapter Two the structure of the hmCMP hydrolase, 
BcmB, is discussed in context of its relationship to other N-glycosidase family 
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members.  The structure of BcmB supports the proposed mechanism for hydrolysis 
and the substrate specificity for CMP or hmCMP. 
 BcmD is another enzyme of interest in the BCM biosynthetic pathway.  In 
Chapter Four, the structure of BcmD is discussed and compared to similar enzymes.  
In order to act as a substrate for the thiamin metabolic pathway, BCM must be 
diphosphorylated to BCM-PP.  BcmD is the HMPP kinase responsible for two 
sequential phosphorylations of BCM to create BCM-PP.  This reaction is analogous to 
the diphosphorylation of HMP before ligation with THZ-P to create ThMP (Figure 
1.3).  Before the structure of BcmD was solved, it was not known whether it had 
structural features that allowed it to distinguish between, and possibly favor, BCM 
over HMP.  Structural comparison of BcmD to known HMPP kinases did not reveal 
any structural differences that may favor BCM binding.  Subsequent biochemical 
studies showed that BcmD did not favor BCM over HMP and raises further questions 
about the evolution and regulation of the BCM biosynthetic genes. 
Azinomycin B is another interesting natural product whose biosynthesis 
presents novel biochemistry.  The genes responsible for its biosynthesis were recently 
identified in Streptomyces sahachiroi.  Azinomycin B contains densely assembled and 
uniquely tailored peptide and naphthoate precursors.  Previous reports suggested that 
the S. sahachiroi polyketide synthase SsAziB, encoded by the aziB gene, was the only 
enzyme in the pathway necessary for production of the naphthoate moiety.9  Recent 
findings suggest that SsAziB acts in concert with a thioesterase, SsAziG, to produce 
the naphthoate (Watanabe Lab- manuscript in preparation).   SsAziB polymerizes and 
condenses acetyl-CoA and malonyl-CoA precursor molecules by shuttling the growing 
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polyketide to its various catalytic domains via a covalent CoA linker.  Then SsAziG 
hydrolyzes the 5-methyl-NPA-CoA thioester bond to release the product for later 
incorporation into azinomycin B.  Crystallographic studies of SsAziG with a bound 
product analog, 3-hydroxy-NPA, allowed for modeling of the proposed product, 5-
methyl-NPA.  Structural comparison between SsAziG and related thioesterases leads 
to the proposed SsAziG function and mechanism.  In the proposed mechanism, the 
azinomycin B naphthoate moiety is transferred by from the SsAziB CoA to the 
SsAziG active site glutamate.   The NPA fragment is then released for incorporation 
into azinomycin B by hydrolysis of the covalent enzyme-substrate bond.  This 
mechanism is very similar to other hotdog-fold thioesterases that hydrolyze the 
covalent bond between a metabolite and coenzyme A.10  Because of the complexity 
and antitumor properties of the azinomycins, their biosynthesis is of continued interest 
to chemists and biologists.  Future structural studies involving enzymes in this 
pathway will provide a greater understanding of their functions and mechanisms.  
Armed with this information, a detailed picture of azinomycin B biosynthesis will 
emerge, enabling synthetic chemists and biochemists to exploit its chemical properties 
for future studies.  The role SsAziG plays in NPA synthesis presents a previously 
unexplored component necessary for azinomycin B biosynthesis.  Its relationship to 
AziB adds to the understanding of the highly complex PKS enzymes that are just now 
beginning to be biochemically and structurally analyzed. 
The work done on the bacimethrin and azinomycin B biosynthesis pathways, 
as well as the NDT superfamily members, are examples where X-ray crystallography 
provided valuable biochemical information.  The structures elucidated in the preceding 
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studies and supporting biochemical characterization revealed interesting functional 
and mechanistic possibilities.   Each of the unique structures discussed- MilB, BcmB, 
Cb-thiaminase I, BcmD and SsAziG- provided an opportunity to better understand 
how these biologically relevant enzymes catalyze complex chemical reactions.   
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